Cholinergic and lipid mediators crosstalk in Covid-19 and the impact of

2 glucocorticoid therapy

1

- 3 *Malena M. Pérez, Ph.D.¹; *Vinícius E. Pimentel, B.Sc.^{1,7}; *Carlos A. Fuzo, Ph.D.^{1,8}
- 4 *Pedro V. da Silva-Neto, M.Sc.^{1,8,9}; Diana M. Toro, M.Sc.^{1,8,9}; Camila O. S. Souza,
- 5 M.Sc. ^{1,7}; Thais F. C. Fraga-Silva, Ph.D. ^{2,7}; Luiz Gustavo Gardinassi, Ph.D. ¹²; Jonatan C.
- 6 S. de Carvalho^{1,5}; Nicola T. Neto^{1,10}; Ingryd Carmona-Garcia^{1,5}; Camilla N. S. Oliveira,
- 7 B.Sc.^{1,7}; Cristiane M. Milanezi, B.Sc.² Viviani Nardini Takahashi, Ph.D.¹; Thais Canassa
- 8 De Leo, M.Sc.^{1,8}; Lilian C. Rodrigues, Ph.D.¹; Cassia F. S. L. Dias, B.Sc.^{1,8}; Ana C.
- 9 Xavier¹⁰; Giovanna S. Porcel¹⁰; Isabelle C. Guarneri¹⁰; Kamila Zaparoli¹¹; Caroline T.
- Garbato¹¹; Jamille G. M. Argolo, M. Sc¹¹; Ângelo A. F. Júnior, M.Sc.¹¹; Marley R.
- 11 Feitosa, M.D.^{3,14}; Rogerio S. Parra, M.D.^{3,14}; José J. R. da Rocha, M.D.³; Omar Feres,
- 12 M.D.^{3,14}; Fernando C. Vilar, M.D.^{4,14}; Gilberto G. Gaspar, M.D.⁴; Rafael C. da Silva,
- 13 B.Sc. 13; Leticia F. Constant, B.M. 13; Fátima M. Ostini, B.M. 13; Alessandro P. de Amorim,
- 14 M.Sc.¹³; Augusto M. Degiovani, B.M.¹³; Dayane P. da Silva¹³, B.Sc.; Debora C.
- Nepomuceno, B.Sc.N. 13; Rita C. C. Barbieri, B.Sc.N. 14; Isabel K. F. M. Santos, Ph.D. 2;
- Sandra R. C. Maruyama, Ph.D.⁶; Elisa M. S. Russo, Ph.D.¹; Angelina L. Viana, Ph.D.¹⁰;
- Ana P. M. Fernandes, Ph.D.¹¹; Vânia L. D. Bonato, Ph.D.^{2,7}; Cristina R. B. Cardoso,
- Ph.D.^{1,7}†; Carlos A. Sorgi, Ph.D.^{5,9}†; Marcelo Dias-Baruffi, Ph.D.^{1,8}†; and Lúcia H.
- 19 Faccioli, Ph.D.^{1,7}†§

20

- *Equal contribution: Malena Martínez Pérez, Ph.D.; Vinícius Eduardo Pimentel, B. Sc;
- 22 Carlos A. Fuzo, Ph.D. and Pedro Vieira da Silva-Neto, M.Sc.
- †Senior authors with equal contribution: Cristina R. B. Cardoso, Ph.D.; Carlos A.
- Sorgi, Ph.D.; Marcelo Dias-Baruffi; Ph.D. and Lúcia Helena Faccioli, Ph.D.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 **Corresponding author**: Lúcia Helena Faccioli, Ph.D. (faccioli@fcfrp.usp.br)
- 27 Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de
- 28 Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP
- 29 Av. do Café, s/n - Vila Monte Alegre, Ribeirão Preto - SP, 14040-900, Ribeirão Preto,
- 30 São Paulo, Brazil. FCFRP-USP, Bloco S, Sala 96A.
- 32 1 - Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de
- 33 Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP,
- 34 Ribeirão Preto, São Paulo, Brazil;

- 35 2 - Departamento de Bioquímica e Imunologia. Faculdade de Medicina de Ribeirão Preto
- 36 - FMRP, Universidade de São Paulo-USP, São Paulo, Brazil;
- 37 3 - Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto -
- 38 FMRP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;
- 39 4 - Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto - FMRP,
- 40 Universidade de São Paulo-USP, São Paulo, Brazil;
- 41 5 - Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto
- 42 - FFCLRP. Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;
- 43 6 - Departamento de Genética e Evolução, Centro de Ciências Biológicas e da Saúde
- 44 Universidade Federal de São Carlos - UFSCar, São Carlos, São Paulo, Brazil;
- 45 7 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Faculdade de Medicina
- 46 de Ribeirão Preto - FMRP, Universidade de São Paulo-USP, Ribeirão Preto São Paulo,
- 47 Brazil;

- 48 8 - Programa de Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia,
- 49 Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São
- 50 Paulo - USP, Ribeirão Preto, São Paulo, Brazil;
- 51 9 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Instituto de Ciências
- 52 Biológicas, Universidade Federal do Amazonas - UFAM, Manaus, Amazonas, Brazil;
- 53 10 - Departamento de Enfermagem Materno-Infantil e Saúde Pública, Escola de
- 54 Enfermagem de Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto,
- 55 São Paulo, Brazil;
- 56 11 - Departamento de Enfermagem Geral e Especializada, Escola de Enfermagem de
- 57 Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo,
- 58 Brazil;
- 12 Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás -59
- 60 UFG, Goiânia, Goiás, Brazil;
- 61 13 - Hospital Santa Casa de Misericórdia de Ribeirão Preto, Ribeirão Preto, São Paulo,
- 62 Brazil;
- 63 14 - Hospital São Paulo, Ribeirão Preto, São Paulo, Brazil.

Abstract

64

65 Cytokine storms and hyperinflammation, potentially controlled by glucocorticoids, occur 66 in COVID-19; the roles of lipid mediators and acetylcholine (ACh) and how 67 glucocorticoid therapy affects their release in Covid-19 remain unclear. Blood and 68 bronchoalveolar lavage (BAL) samples from SARS-CoV-2- and non-SARS-CoV-2-69 infected subjects were collected for metabolomic/lipidomic, cytokines, soluble CD14 70 (sCD14), and ACh, and CD14 and CD36-expressing monocyte/macrophage 71 subpopulation analyses. Transcriptome reanalysis of pulmonary biopsies was performed 72 by assessing coexpression, differential expression, and biological networks. Correlations 73 of lipid mediators, sCD14, and ACh with glucocorticoid treatment were evaluated. This 74 study enrolled 190 participants with Covid-19 at different disease stages, 13 hospitalized 75 non-Covid-19 patients, and 39 healthy-participants. SARS-CoV-2 infection increased 76 blood levels of arachidonic acid (AA), 5-HETE, 11-HETE, sCD14, and ACh but 77 decreased monocyte CD14 and CD36 expression. 5-HETE, 11-HETE, cytokines, ACh, 78 and neutrophils were higher in BAL than in circulation (fold-change for 5-HETE 389.0; 79 11-HETE 13.6; ACh 18.7, neutrophil 177.5, respectively). Only AA was higher in 80 circulation than in BAL samples (fold-change 7.7). Results were considered significant 81 at P<0.05, 95%CI. Transcriptome data revealed a unique gene expression profile 82 associated with AA, 5-HETE, 11-HETE, ACh, and their receptors in Covid-19. 83 Glucocorticoid treatment in severe/critical cases lowered ACh without impacting disease 84 outcome. We first report that pulmonary inflammation and the worst outcomes in Covid-85 19 are associated with high levels of ACh and lipid mediators. Glucocorticoid therapy 86 only reduced ACh, and we suggest that treatment may be started early, in combination 87 with AA metabolism inhibitors, to better benefit severe/critical patients.

Introduction

Individuals Covid-19 may present asymptomatically or with manifestations ranging from acute respiratory distress syndrome to systemic hyperinflammation and organ failure, events attributed to cytokine storms¹. Free polyunsaturated fatty acids, such as AA and derivative eicosanoids, regulate inflammation^{2,3}, yet their role in Covid-19 has not been well investigated.

ACh, which is released by nerves⁴, leukocytes⁵, and airway epithelial cells⁶, regulates metabolism⁷, cardiac function⁸, airway inflammation⁹, and cytokine production¹⁰, all of which occur in Covid-19. It is known that eicosanoids stimulate ACh release³, but crosstalk between cholinergic and lipid mediator pathways in Covid-19 still need to be clarified.

In this study, levels of lipid mediators, ACh, and other inflammatory markers in blood and BAL from patients with Covid-19 who were treated or not with glucocorticoids were compared to those of non-Covid-19 and healthy-participants. Moreover, lung biopsy transcriptome reanalysis data from Covid-19 and non-Covid-19 patients corroborated our findings.

Methods

Study design and blood collection

This observational, analytic, and transversal study was conducted from June to November 2020. All participants were over 16 years old and chosen according to the inclusion and exclusion criteria described in Table S1 and in the protocol, after providing signed consent. Blood samples collected from patients positive for Covid-19 (n=190) were analyzed by RT-qPCR (Biomol OneStep/Covid-19 kit; Institute of Molecular Biology of Paraná - IBMP Curitiba/PR, Brazil) using nasopharyngeal swabs and/or

serological assays to detect IgM/IgG/IgA (SARS-CoV-2® antibody test; Guangzhou Wondfo Biotech, China). Samples obtained from a cohort of SARS-CoV-2-negative healthy participants were used as controls (n=39). Participants positive for Covid-19 were categorised as asymptomatic-mild (n=43), moderate (n=44), severe (n=54), or critical (n=49). The criteria for the clinical classification of patients were defined at the time of sample collection, as shown in Table S1. Peripheral blood samples were obtained by venous puncture from patients upon their first admission and/or during the period of hospitalisation at two medical centres, Santa Casa de Misericordia de Ribeirão Preto and Hospital Sao Paulo at Ribeirão Preto, São Paulo State, Brazil. Blood samples from healthy controls and asymptomatic-mild non-hospitalized participants were collected either at the Centre of Scientific and Technological Development "Supera Park" (Ribeirão Preto, São Paulo State, Brazil) or in the home of patients receiving at-home care. The plasma was separated from whole blood samples and stored at -80°C. For lipidomic and metabolomic analyses, 250 µL of plasma was stored immediately in methanol (1:1 v/v). Lipidomic and metabolomic analyses were performed by mass spectrometry (LC-MS/MS), while a cytokines, sCD14, and ACh were quantified using CBA flex Kit (flow cytometer assay) or commercial ELISA. The expression levels of CD14, CD36, CD16, and HLA-DR in cells were evaluated by flow cytometry following the gate strategy (Figure S2).

Ethical considerations

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

All participants provided written consent in accordance with the regulations of the *Conselho Nacional de Pesquisa em Humanos* (CONEP) and the Human Ethical Committee from *Faculdade de Ciências Farmacêuticas de Ribeirão Preto* (CEP-FCFRP-USP). The research protocol was approved and received the certificate of Presentation and Ethical Appreciation (CAAE: 30525920.7.0000.5403). The sample size was

determined by the convenience of sampling, availability at partner hospitals, agreement to participate, and the pandemic conditions within the local community (more information in the Protocol).

Bronchoalveolar lavage fluid (BAL) collection and processing

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

BAL fluids were collected from hospitalised Covid-19 patients at the severe or critical stages of disease (n=32) to assess their lung immune responses. Control samples were obtained from hospitalised intubated donors negative for SARS-CoV-2 (n=13) (as certified by SARS-CoV-2-negative PCR), referred to as non-Covid-19 patients, who were intubated because of the following primary conditions: bacterial pneumonia, abdominal septic shock associated with respiratory distress syndrome, pulmonary atelectasis due to phrenic nerve damage, or pulmonary tuberculosis. BAL fluid was collected as previously described¹¹, using a siliconized polyvinylchloride catheter (Mark Med, Porto Alegre, Brazil) with a closed Trach Care endotracheal suction system (Bioteque Corporation, Chirurgic Fernandes Ltd., Santana Parnaíba, Brazil) and sterile 120 mL polypropylene flask (Biomeg-Biotec Hospital Products Ltd., Mairiporã, Brazil) under aseptic conditions. Approximately 5–10 mL of bronchoalveolar fluid was obtained and placed on ice for processing within 4 h. The BAL fluids were placed into 15-mL polypropylene collection tubes and received half volume of their volume of phosphate buffered saline (PBS) 0.1 M (2:1 v/v) in relation to the total volume of each sample. After centrifugation (700 × g, 10 min), the supernatants of the BAL fluid were recovered and stored at -80°C. For lipidomic and metabolomic analyses, 250 µL of these supernatants were stored immediately in methanol (1:1 v/v). Subsequently, the remaining BAL fluid was diluted in 10 mL of PBS and gently filtered through a 100-um cell strainer (Costar, Corning, NY, USA) using a syringe plunger. The resulting material was used for cytokine and acetylcholine (ACh) quantification. The BAL fluids were centrifuged ($700 \times g$, 10 min)

and the red blood cells were lysed using 1 mL of ammonium chloride (NH₄Cl) buffer 0.16 M for 5 min. The remaining airway cells were washed with 10 mL of PBS, resuspended in PBS–2% heat-inactivated foetal calf serum, and counted with Trypan blue using an automated cell counter (Countess, Thermo Fisher Scientific, Waltham, MA, USA). The leukocyte numbers were adjusted to 1×10^9 cells/L for differential counts and 1×10^6 cells/mL for flow cytometry analysis. All procedures were performed in a Level 3 Biosafety Facility (*Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo*).

Data collection

The electronic medical records of each patient were carefully reviewed. Data included sociodemographic information, comorbidities, medical history, clinical symptoms, routine laboratory tests, immunological tests, chest computed tomography (CT) scans, clinical interventions, and outcomes (more information in the Protocol). The information was documented on a standardised record form, as indicated in Tables S1, S2, and S3. Data collection of laboratory results included first-time examinations within 24 h of admission, defined as the primary endpoint. The secondary endpoint was clinical outcome (death or recovery).

Clinical laboratory collection

For hospitalised patients, blood examinations were performed by clinical analysis laboratories at their respective hospitals. Blood examinations of healthy participants and non-hospitalized patients were performed at *Serviço de Análises Clínicas* (SAC), *Departamento de Análises Clínicas, Toxicológicas e Bromatológicas* of the *Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão*

Preto, São Paulo, Brazil. The blood samples were used to measure for liver and kidney function, myocardial enzyme spectrum, coagulation factors, red blood cells, haemoglobin, platelets, and total and differential leukocytes using automated equipment. Similarly, the absolute numbers of leukocytes in the BAL fluid were determined in a Neubauer Chamber with Turkey solution. For the counts of differential leukocytes in the BAL, 100 µL of the fluid was added to cytospin immediately after collection to avoid any interference on cell morphology. Differential leukocyte counts were conducted using an average of 200 cells after staining with Fast Panoptic (LABORCLIN; Laboratory Products Ltd, Pinhais, Brazil) and examined under an optical microscope (Zeiss EM109; Carl Zeiss AG, Oberkochen, Germany) with a 100× objective (immersion oil) equipped with a Veleta CCD digital camera (Olympus Soft Imaging Solutions Gmbh, Germany) and ImageJ (1.45s) (National Institutes of Health, Rockville, MD, USA)¹². Lymphocytes, neutrophils, eosinophils, and monocytes/macrophages identified were and morphologically characterised, and their lengths and widths were measured (100×).

High-performance liquid chromatography coupled with tandem Mass Spectrometry

(LC-MS/MS) assay

Reagents

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Eicosanoids, free fatty acids (AA, EPA, and DHA), and metabolites as molecular weight standards (MWS) and deuterated internal standards were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). HPLC-grade acetonitrile (ACN), methanol (MeOH), and isopropanol were purchased from Merck (Kenilworth, NJ, USA). Ultrapure deionised water (H₂O) was obtained using a Milli-Q water purification system (Merck-Millipore, Kenilworth, NJ, USA). Acetic acid (CH₃COOH) and ammonium hydroxide (NH₄OH) were obtained from Sigma Aldrich (St. Louis, MO, USA).

Sample preparation and extraction

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

The plasma (250 µL) in EDTA-containing tubes (Vacutainer® EDTA K2; BD Diagnostics, Franklin Lakes, NJ, USA) and BAL (250 μL) samples were stored in MeOH (1:1, v/v) at -80°C. Three additional volumes of ice-cold absolute MeOH were added to each sample overnight at -20°C for protein denaturation and after lipid solid-phase extraction (SPE). To each sample, 10 µL of internal standard (IS) solution was added, centrifuged at $800 \times g$ for 10 min at 4°C. The resulting supernatants were collected and diluted with deionised water (ultrapure water; Merck-Millipore, Kenilworth, NJ, USA) to obtain a MeOH concentration of 10% (v/v). In the SPE extractions, a Hypersep C18-500 mg column (3 mL) (Thermo Scientific-Bellefonte, PA, USA) equipped with an extraction manifold collector (Waters-Milford, MA, USA) was used. The diluted samples were loaded into the pre-equilibrated column and washing using 2 mL of MeOH and H₂O containing 0.1% acetic acid, respectively. Then, the cartridges were flushed with 4 mL of H₂O containing 0.1% acetic acid to remove hydrophilic impurities. The lipids that had been adsorbed on the SPE sorbent were eluted with 1 mL of MeOH containing 0.1% acetic acid. The eluates solvent was removed in vacuum (Concentrator Plus, Eppendorf, Germany) at room temperature and reconstituted in 50 μ L of MeOH/H2O (7:3, v/v) for LC-MS/MS analysis.

LC-MS/MS analysis and lipids data processing

Liquid chromatography was performed using an Ascentis Express C18 column (Supelco, St. Louis, MO, USA) with 100×4.6 mm and a particle size of 2.7 μ m in a high-performance liquid chromatography (HPLC) system (Nexera X2; Shimadzu, Kyoto, Japan). Then, $20~\mu$ L of extracted sample was injected into the HPLC column. Elution was carried out under a binary gradient system consisting of Phase A, comprised of H₂O,

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

ACN, and acetic acid (69.98:30:0.02, v/v/v) at pH 5.8 (adjusted with NH₄OH), and Phase B, comprised of ACN and isopropanol (70:30, v/v). Gradient elution was performed for 25 min at a flow rate of 0.5 mL/min. The gradient conditions were as follows: 0 to 2 min, 0% B; 2 to 5 min, 15% B; 5 to 8 min, 20% B; 8 to 11 min, 35% B; 11 to 15 min, 70% B; and 15 to 19 min, 100% B. At 19 min, the gradient was returned to the initial condition of 0% B, and the column was re-equilibrated until 25 min. During analysis, the column samples were maintained at 25°C and 4°C in the auto-sampler. The HPLC system was directly connected to a TripleTOF 5600+ mass spectrometer (SCIEX-Foster, CA, USA). An electrospray ionisation source (ESI) in negative ion mode was used for high-resolution multiple-reaction monitoring (MRMHR) scanning. An atmospheric-pressure chemical ionisation probe (APCI) was used for external calibrations of the calibrated delivery system (CDS). Automatic mass calibration (<2 ppm) was performed periodically after each of the five sample injections using APCI Negative Calibration Solution (Sciex-Foster, CA, USA) injected via direct infusion at a flow rate of 300 µL/min. Additional instrumental parameters were as follows: nebuliser gas (GS1), 50 psi; turbo gas (GS2), 50 psi; curtain gas (CUR), 25 psi; electrospray voltage (ISVF), -4.0 kV; temperature of the turbo ion spray source, 550°C. The dwell time was 10 ms, and a mass resolution of 35,000 was achieved at m/z 400. Data acquisition was performed using AnalystTM software (SCIEX- Foster, CA, USA). Qualitative identification of the lipid species was performed using PeakViewTM (SCIEX-Foster, CA, USA). MultiQuantTM (SCIEX-Foster, CA, USA) was used for the quantitative analysis, which allows the normalisation of the peak intensities of individual molecular ions using an internal standard for each class of lipid. The quantification of each compound was performed using internal standards and calibration curves, and the specific mass transitions of each lipid were determined

according to our previously published method¹³. The final concentration of lipids was normalised by the initial volume of plasma or BAL fluid (ng/mL).

Metabolomics analysis

Metabolite was extracted and samples were transferred to autosampler vials for LC–MS analysis using TripleTOF5600+ Mass Spectrometer (Sciex-Foster, CA, USA) coupled to an ultra-high-performance liquid chromatography (UHPLC) system (Nexera X2; Shimadzu, Kyoto, Japan). Reverse-phase chromatography was performed similarly to lipids analyses above. Mass spectral data were acquired with negative electrospray ionisation, and the full scan of mass-to-charge ratio (*m/z*) ranged from 100 to 1500. Proteowizard software¹⁴ was used to convert the wiff files into *mz* XML files. Peak peaking, noise filtering, retention time, *m/z* alignment, and feature quantification were performed using apLCMS¹⁵. Three parameters were used to define a metabolite feature: mass-to-charge ratio (*m/z*), retention time (min), and intensity values. Data were log₂ transformed and only features detected in at least 50% of samples from one group were used in further analyses. Missing values were imputed using half the mean of the feature across all samples. Mummichog (version 2) was used for metabolic pathway enrichment analysis (mass accuracy under 10 ppm)¹⁶.

Acetylcholine measurement

ACh was measured in heparinized plasma (SST® Gel Advance®; BD Diagnostics, Franklin Lakes, NJ, USA) and in BAL using a commercially available immunofluorescence kit (ab65345; Abcam, Cambridge, UK) according to the manufacturer's instructions. Briefly, ACh was converted to choline by adding the enzyme acetylcholinesterase to the reaction, which allows for total and free-choline measurement. The amount of ACh present in the samples was calculated by subtracting the free choline

from the total choline. The products formed in the assay react with the choline probe and can be measured by fluorescence with excitation and emission wavelengths of 535 and 587 nm, respectively (Paradigm Plate Reader; SpectraMax, San Diego, CA, USA). The concentration of ACh was analysed using SoftMax® software (SpectraMax, Molecular Devices, Sunnyvale, CA, USA), expressed as pmol.mL⁻¹.

Soluble CD14 (sCD14) measurement

Samples from heparinized plasma (SST® Gel Advance®; BD Biosciences, Franklin Lakes, NJ, USA) were placed in 96-well plates. The concentration of sCD14 was determined using an ELISA kit (DY383; R&D Systems, Minneapolis, MN, USA), following the manufacturer's instructions, expressed as pg.mL⁻¹.

Flow Cytometry

Uncoagulated blood samples in EDTA-containing tubes (Vacutainer® EDTA K2; BD Biosciences) were processed for flow cytometry analysis of circulating leukocytes. Whole blood (1 mL) was separated and red blood cells were lysed using RBC lysis buffer (Roche Diagnostics GmbH, Mannheim, GR). Leukocytes were washed in PBS containing 5% foetal bovine serum (FBS) (Gibco[™], USA), centrifuged, and resuspended in Hank's balanced salt solution (Sigma-Aldrich, Merck, Darmstadt, Germany) containing 5% FBS, followed by surface antigen staining. Similarly, cells obtained from BAL fluid were processed for flow cytometry assays. Briefly, cells were stained with Fixable Viability Stain 620 (1:1000) (BD Biosciences) and incubated with monoclonal antibodies specific for CD14 (1:100) (M5E2; Biolegend), HLA-DR (1:100) (G46-6; BD Biosciences), CD16 (1:100) (3G8; Biolegend), and CD36 (1:100) (CB38, BD Biosciences) for 30 min at 4°C. Stained cells were washed and fixed with BD Cytofix[™] Fixation Buffer (554655; BD Biosciences, San Diego, CA, USA). Data acquisition was performed using a LSR-

FortessaTM flow cytometer (BD Biosciences, San Jose, CA, USA) and FACS-Diva software (version 8.0.1) (BD Biosciences, Franklin Lakes, NJ, USA). For the analysis, 300,000 events were acquired for each sample. Data were evaluated using FlowJo® software (version 10.7.0) (Tree Star, Ashland, OR, USA) to calculate the cell frequency, dimensionality reduction, and visualisation using t-distributed stochastic neighbour embedding. Gate strategy performed as described before ¹⁷, as shown in Figure S2.

Cytokine Measurements

The cytokines interleukin (IL)-6, IL-8, IL-16, IL-10, and tumour necrosis factor (TNF) were quantified in heparinized plasma and BAL fluid samples using a BD Cytometric Bead Array (CBA) Human Inflammatory Kit (BD Biosciences, San Jose, CA, USA), according to manufacturer's instructions. Briefly, after sample processing, the cytokine beads were counted using a flow cytometer (FACS Canto TM II; BD Biosciences, San Diego, CA, USA), and analyses were performed using FCAP Array (3.0) software (BD Biosciences, San Jose, CA, USA). The concentrations of cytokines were expressed as pg.mL⁻¹.

Re-analysis of transcriptome data from lung biopsies of patients with Covid-19

To gain a better understanding of the correlation between the altered concentrations of ACh, AA, and AA-metabolites detected in the plasma and BAL fluid of severe/critical Covid-19 patients, we performed a new analysis by re-using a previously published transcriptome open dataset ¹⁸, deposited in the Gene Expression Omnibus repository under accession no. GSE150316 ¹⁹. We used transcriptome data from lung samples (n=46) from patients with Covid-19 (n=15), seven of which displayed a low viral load and eight a high viral load, and non-Covid-19 patients (n=5) with other pulmonary illnesses (negative control). Patients with a high viral load had meantime periods of

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

hospital stays (3.6±2.2 days) and duration of illness (7.2±3.02 days) shorter than the patients with low viral load (14±7.9 and 19±4.9 days, respectively), as described by the authors of the public data source ¹⁸. Hence, for analysis purposes, all patient samples were grouped into four classifications: Covid-19 (CV), Covid-19 low viral load (CVL), Covid-19 high viral load (CVH), and non-Covid-19 (NCV). The strategy for reanalysing the transcriptome was implemented according to three consecutive steps: (i) co-expression analysis, (ii) differential expression analysis, and (iii) biological network construction. Initially, for the co-expression study, normalised transcriptome data in log₂ of reads per million (RPM) were filtered by excluding non-zero counts in at least 20% of the samples. Next, the selected genes were explored in the R package Co-Expression Modules identification Tool (CEMITool) ²⁰, using a *p*-value of 0.05 as the threshold for filtering. Then, the co-expression modules were analysed for the occurrence of ACh and AA genes list obtained from the Reactome pathways ²¹, as well as the Covid-19-related genes obtained from the literature (Supplementary Appendix I). Next, differential gene expression between samples from the lung biopsy transcriptome (CV, NCV, CVL, and CVH) was measured using the DESeq2 package ²², with p-values adjusted using the Benjamini and Hochberg method ²³. The list of differentially express genes (DEGs) generated for all comparisons was filtered from the genes listed in Supplementary Appendix I, considering the values of log₂ of fold-change (FC) greater than 1 $(|\log 2(FC)|>1)$ and adjusted p<0.05. Finally, a first-order biological network was constructed using co-expression module(s) containing genes associated with the ACh and AA pathways to characterise the interplay between these mediators in combination with Covid-19 severity markers, as well as to identify relevant DEGs and hub genes in this network, using the BioGRID repository ²⁴. The networks were constructed, analysed, and graphically represented using the R packages igraph ²⁵, Integraph ²⁶, and genetwork ²⁷.

Due to the substantial influence of glucocorticoid treatment on the levels of some mediators, we measured the sensitivity of genes from the differential expression analysis between CV samples from patients who underwent treatment (CTC, three patients and ten samples) and patients who were not treated (NCTC, 12 patients and 36 samples), as previously described ¹⁸.

Statistical Analysis

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Two-tailed tests were used for the statistical analysis, with a significance value of p < 0.05 and a confidence interval of 95%. The data were evaluated for a normal distribution using the Kolmogorov-Smirnov test. The parametric data were analysed using unpaired t-tests (for two groups) or one-way ANOVA followed by Tukey's multiple comparison tests for three or more groups simultaneously. For data that did not display a Gaussian distribution, Mann-Whitney (for two-group comparisons) or Kruskal-Wallis testes were used, followed by Dunn's post-tests for analysis among three or more groups. The cytokine network data in patients with Covid-19 were analysed using significant Spearman's correlations at p < 0.05. Data were represented by connecting edges to highlight positive strong ($r \ge 0.68$; thick continuous line), moderate (0.36 $\ge r < 0.68$; thinner continuous line), or weak (0 > r < 0.36; thin continuous line) and negative strong $(r \le -0.68$; thick dashed line), moderate $(-0.68 > r \le -0.36$; thinner dashed line), or weak (-0.36 < r > 0); thin dashed line), as proposed previously ^{28,29}. The absence of a line indicates the non-existence of the relationship. The Venn diagrams were elaborated using the online tool Draw Venn Diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/). The results were tabulated using GraphPad Prism software (version 8.0) and the differences were considered statistically significant at p<0.05. See the Additional Statistical Report section for more information. Some of the confounding variables associated with Covid-19 (age, sex, obesity, hypertension, and diabetes mellitus) were

analysed for their potential impacts on the main analytical procedures of this study, such as ACh, AA, 5-HETE, and 11- HETE measurements of the plasma (healthy, asymptomatic-to-mild, moderate, severe, and critical patients) and BAL (severe and critical patients) samples. This analysis was performed using the Kruskal-Wallis, Mann-Whitney, Spearman's correlation, or Chi-square (χ 2) tests (Table S7-S9).

Results

Study Population

This study enrolled 39 healthy-participants, 13 hospitalized non-Covid-19, and 190 Covid-19 patients aged 16-96 years from April to November 2020. The 190 Covid-19 patients were categorized as having asymptomatic-to-mild (n=43), moderate (n=44), severe (n=54), or critical (n=49) disease (Table S2).

Covid-19 Modifies Circulating Soluble Mediators and Cell Populations

To determine whether SARS-CoV-2 infection alters the metabolism of lipid mediators, we used high-resolution sensitive mass spectrometry to perform targeted eicosanoid analysis and nontargeted metabolomics using plasma from healthy-participants and Covid-19 patients. In total, 8,791 metabolite features were present in at least 50% of all samples, and the relative abundance of 595 metabolite features (FDR adjusted P<0.05) was altered in the groups studied (Figure 1A). Two-way hierarchical clustering based on these significant metabolite features resulted in three clear clusters: one for severe/critical Covid-19 patients, one for healthy-participants and one for asymptomatic-to-mild and moderate Covid-19 (Figure S1A). Pathway analysis revealed the top significant metabolic pathways to be enriched in features involved in fatty acid biosynthesis, metabolism, activation, and oxidation (Figure 1B). Compared to healthy-

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

participants, tentative metabolite annotations suggested an increased abundance of fatty acids (FFAs), such as linoleic acid, tetradecanoate, dodecanoate and AA, in COVID-19 (Figure 4C-F). Among the identified lipids, AA was the most abundant, and its levels correlated with the severity of Covid-19 (Figure 1F). Linoleic acid can be metabolized to AA, which in turn is a substrate for eicosanoids, such as 5-hydroxyeicosatetraenoic acid (5-HETE) and 11-hydroxyeicosatetraenoic acid (11-HETE) (Figure 1G, 1H); both molecules with function in the immune response. Overall, the increased plasma levels of AA in Covid-19 indicate that it predicts disease severity. As eicosanoids induce cell recruitment and regulate immune responses, we next determined the profile of immune cells and soluble mediators in whole blood and plasma of patients with Covid-19 and healthy-participants. According to whole-blood analysis, absolute leukocyte and neutrophil counts (Figure 2A, 2B) were significantly higher but lymphocyte counts (Figure 2C) significantly lower in patients with severe/critical disease than in those with moderate disease. Eosinophil (Figure 2D) and basophil counts (Figure 2E) were reduced severe disease compared to asymptomatic and moderate disease. Although no differences in total monocyte counts among the groups (Figure 2F) were observed based on CD16, CD14 and HLA-DR, expression of membrane CD14 was reduced in all SARS-CoV-2-infected patients compared to healthy-participants (Figure 2G; Figure S2, S3). In parallel, CD36 expression was decreased in monocytes from patients with severe/critical disease (Figure 2H), but sCD14 was increased only in plasma from critical patients (Figure 2I). We did not detect differences in classic or non-classic monocytes, but the percentage of intermediate monocytes was decreased in all SARS-CoV-2-infected participants compared to healthy-participants (Figure 2J, 2K, 2L). Based on plasma cytokine level analysis, patients with moderate, severe, and critical disease

share a Covid-19 cytokine profile defined by increased IL-8, IL-6, and IL-10 (Figure 2M,

2N, 2Q) levels, with unaltered IL-1β and TNF levels (Figure 2O, 2P).

Covid-19 Induces Strong Lung Responses

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

We performed measurements of BAL from hospitalized Covid-19 and non-Covid-19 patients. Changes in lung metabolomics induced by SARS-CoV-2 infection (Figure 3A; Figure S1B) included alterations in sphingolipids, beta oxidation of trihydroxyprostanoil-CoA, biosynthesis and metabolism of steroidal hormones, vitamin D3, and glycerophospholipids (Figure 3B). We also evaluated AA and its metabolites. Despite no differences in AA, levels of 5-HETE and 11-HETE in BAL were significantly higher in Covid-19 than in non-Covid-19 patients, though other metabolites did not differ between these groups (Figure 3C). When assessing leukocytes in BAL between the patient groups, we found no differences in total or differential counts, with the exception of lymphocyte numbers (Figure 3D, 3E). In contrast to eicosanoids, cytokine profiles in Covid-19 and non-Covid-19 patients were similar (Figure 3F), suggesting that lipid mediators contribute to the pathophysiological processes induced by SARS-CoV-2. Interestingly, we observed a significant reduction in classical (Figure 3G) and intermediate (Figure 3H) monocytes in BAL from Covid-19 patients. In parallel, CD14 and CD36 expression in monocyte was lower in BAL of Covid-19 than in that of non-Covid-19 patients (Figure 3I, 3J).

Acetylcholine, Cytokines and Eicosanoids are Higher in the Lung Micro-

Environment

We compared systemic and lung responses only in patients with severe/critical Covid-19 and found significantly higher levels of cytokines in BAL than in blood (Figure 4A). When comparing lipid mediator levels in either compartment from the same Covid-

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

19 patients, we detected lower AA but higher levels of 5-HETE and 11-HETE in BAL than in blood (Figure 4B, 4C, 4D). Previous results from our group³ have shown that eicosanoids contribute to ACh release. Therefore, we next measured ACh in patients with Covid-19 and observed higher plasma levels of ACh in patients with Covid-19; in addition, ACh was elevated in patients with severe/critical disease compared with those with asymptomatic/moderate disease or healthy-participants (Figure 4E). Unexpectedly, in patients with severe/critical Covid-19, ACh levels in BAL were 10-fold higher than those in serum, and patients treated with glucocorticoids showed decreases in ACh in both compartments (Figure 4F, 4G). Interesting, neutrophil counts were higher in BAL, as these cells produce high levels of 5-HETE and IL-1\beta, both of which are mediators of ACh release^{30,31} (Figure 4H). Correlation analysis was then performed to evaluate the relationship between eicosanoids, cytokines, sCD14 and ACh in patients with Covid-19. When comparing blood samples from all patients, we detected strong correlations between ACh versus IL-1\beta and moderate correlations between ACh versus AA. A substantial number of interactions between AA and its metabolites and between cytokines and eicosanoids were observed (Figure 4I; Figure S4A). Correlations among all parameters were also observed in BAL (Figure 4J; Figure S4B). To evaluate the benefit of glucocorticoid treatments and their relationship with eicosanoids, CD14 and ACh, we analysed the intersections in a Venn diagram of blood and BAL from severe/critical Covid-19. The results showed that treatment of Covid-19 with glucocorticoids did not have a significant influence on eicosanoid or sCD14 release in patients with more severe stages of disease; in critical patients, however, reductions of 44% and 65% in ACh levels in blood and BAL, respectively, were observed (Figure 4K-4Q; Figure S5). These findings suggest that the use of glucocorticoids has a positive effect on resolution of the

inflammatory process because they reduce ACh release, which directly or indirectly stimulates cell recruitment and proinflammatory mediator release.

Altered Expression of Acetylcholine and Arachidonic Acid Pathway Genes in Lung

Biopsies From Some Covid-19 Patients

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

In this study, we reanalysed the lung biopsy transcriptome from Covid-19 patients to evaluate expression of ACh and AA pathway genes (Supplementary Appendix I). These genes were coexpressed only in a single module (M1) that included genes related to the ACh release cycle, AA metabolism, cholinergic and eicosanoid receptors, and biomarkers of Covid-19 severity (Figure 5A; Table S4; Supplementary Appendix II). Furthermore, expression of nearly all genes was upregulated in some deceased Covid-19 patients with long hospital stays and low viral loads (Figure 5B; Figure S6A; Supplementary Appendix III). These differentially expressed genes populated the biological network and are likely under the action of some hubs (Figure 5C; Supplementary Appendix IV), such as oestrogen receptor II (ESR2) and albumin (ALB). We identified a unique proinflammatory gene expression profile in lung biopsies related to cholinergic and eicosanoid receptors (Figure 5H, 5I; Figure S6B, S6C). In combination with the altered levels of ACh, AA, and AA metabolites found in patient from our cohort, the transcriptome data reported herein strengthen the likelihood that these mediators contribute to Covid-19 severity (Figure 5D-5G). Interestingly, lung samples from Covid-19 patients with short hospital stays and high viral loads did not present this unique expression profile of ACh or AA pathway genes (Figure 5H, 5I; Figure S6B, S6C). Some Covid-19 patients treated versus not with glucocorticoid showed transcript expression of monoglyceride lipase (MGLL) and N-acylethanolamine acid amidase (NAAA) and upregulation of fatty acid amide hydrolase (FAAH), which are involved in the production of AA from endocannabinoid (cases 3, 9, and 11; Figure 5B; Supplementary Appendix

III). Besides, we detected other DEGs in biopsy samples from Covid-19 patients (glucocorticoid-treated versus non-treated) associated with AA, ACh, interferon pathways, and Covid-19 biomarkers (Supplementary Appendix III).

Discussion

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

A consensus is building around the fatal effects of SARS-CoV-2 infection, which is increasingly believed to cause death as a result of systemic hyperinflammation and multiorgan collapse³², secondary to systemic cytokine storms ^{33–35}. However, few studies have compared pulmonary and systemic inflammation ³⁶ or considered the contribution of eicosanoids and neurotransmitters to these effects. In our study, we hypothesised that, in Covid-19, pulmonary cells and leukocytes, in addition to cytokines, release eicosanoids and ACh, mediating local and systemic manifestations. In patients with severe/critical SARS-CoV-2 infection, we found that ACh, 5-HETE, 11-HETE, and cytokines were more abundant in the lung than under systemic conditions. In contrast, only the levels of AA were found to be higher in the circulation than in the BAL fluid. Interestingly, in patients with severe/critical disease who were treated with corticosteroids, only ACh was inhibited. In our study, we compared the lung and systemic responses in association with the lung transcriptome and demonstrated a robust correlation between lipid mediators, neurotransmitters, and their receptors in SARS-CoV-2 infection. However, contrary to what has been suggested by previous studies ^{37,38}, only small amounts of eicosanoids were found in the plasma of patients with severe/critical disease, with significant differences observed only in AA, 5-HETE, and 11-HETE. Interestingly, the levels of 5-HETE and 11-HETE were found to be remarkably higher in BAL, as well as AA in plasma, suggesting that AA and its metabolites mediate responses to Covid-19. 5-HETE induces

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

neutrophil recruitment ³⁹, pulmonary oedema ⁴⁰, and ACh release ³⁰. It is released by human neutrophils, and its esterified form promotes IL-8 secretion ³¹. Unlike the esterified form ³¹, free-5-HETE did not inhibit NETs formation, a key event in Covid-19 ⁴¹. Remarkably, 11-HETE originating from monocytes/macrophages ⁴², endothelial cells 43 , and platelets 44 is induced by hypoxia 45 , IL-1 β 46 , contributes to ACh functions 43 , and inhibits insulin release ⁴⁷. The involvement of AA was confirmed by bioinformatic analyses that identified the expression or upregulation of genes related to AA metabolism and eicosanoid receptors in some lung biopsies. These included the OXER1 gene, which encodes a receptor for AA and 5-HETE which mediates neutrophil activation/recruitment ^{49,50}. Our metabolomic analysis also showed an increase in the plasma AA and linoleic acid levels, similar to a plasma lipidome performed by Schwarz et al., suggesting a strong correlation between lipid mediators and Covid-19 severity ⁵¹. Accordingly, the ELOVL2 gene, which is involved in linoleic acid metabolism and AA synthesis ⁵², was upregulated in lung biopsies. The RNA expression of ALOX5, an enzyme that participates in lipid mediator production, is upregulated in some immune cell types from severe Covid-19 patients ⁵³, and has been detected in the lung biopsies of deceased Covid-19 patients ¹⁸. In contrast to our lung transcriptome re-analysis findings, the expression of cytochrome p450 (CYP) enzymes, which are also involved in lipid mediator generation, was not detected in the peripheral blood mononuclear cells (PBMC) transcriptome re-analysis from severe Covid-19 patients ⁵³. One possible explanation for this contradiction is that Covid-19 is a heterogeneous illness composed of distinct tissue gene expression associated with Covid-19 severity and different immunopathological profiles in infected tissues ^{18,54}. This immunological heterogeneity could be related to two types of evolution of severe Covid-19 patients, one associated with a high viral load and susceptibility to SARS-CoV-2

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

infection, a shorter hospitalisation time, and exudative diffuse alveolar damage, and another associated with a low or undetectable viral load, a mixed lung histopathological profile, and a longer hospitalisation time associated with non-homeostatic pulmonary inflammation ^{18,54,55}. In this context, we found that the expression levels of some lipid mediators and ACh and AA pathway genes varied in the plasma and BAL samples of severe/critical patients, which were found to be preferentially activated in the lungs of deceased Covid-19 patients with low viral loads, long hospitalisation times, and damaging lung inflammation. Nevertheless, it remains unclear whether AA and linoleic acid contribute to host protection ⁵⁶ and tissue damage, or whether they represent a viral escape mechanism. AA is known to directly interact with the virus, reducing its viability and inducing membrane disturbances, disfavouring SARS-CoV-2 entry ^{57–59}. On the other hand, reduced plasma AA levels may be associated with lung injury and poor outcomes in Covid-19 infection ⁶⁰. Within this context, Shen and et al. found lower concentrations of AA in survivors of severe Covid-19 infection ³⁷. However, in the present study, the levels of AA were found to be increased in the plasma of patients who died from severe Covid-19, suggesting that the potential benefits of AA are overcome by a higher production of its proinflammatory metabolites, 5-HETE and 11-HETE. Interestingly, in our cohort, AA, 5-HETE, and 11-HETE were not altered in the plasma or BAL fluid of patients with severe/critical Covid-19 infection who had received glucocorticoid treatment. This may be explained by the fact that AA, in addition to calcium-activated-PLA2 61 also originates from glucocorticoid-insensitive phospholipase ⁶², adipocyte destruction ⁶³, linoleic acid ⁶⁴, or the degradation of endocannabinoids by FAAH 65, a macrophage enzyme detected in SARS-CoV-2-infected patients ⁶⁶. Notably, some CVL Covid-19 patients, regardless of

whether they were treated or not with glucocorticoids, showed transcript expression of

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

MGLL and NAAA, as well as an up-regulation of FAAH and all of the enzymes involved in the production of AA from endocannabinoid ⁶⁷. In addition, we detected other DEGs in biopsy samples (glucocorticoid-treated versus non-treated) associated with AA, ACh, interferon pathways, and Covid-19 biomarkers. Glucocorticoids have been used widely to reduce the morbidity and mortality rates of Covid-19 patients, but have not been effective for all patients ⁶⁸. The mortality rate for glucocorticoid-treated hospitalised Covid-19 patients from our cohort was higher than that reported in the RECOVERY trial and similar to that described in the CoDEX trial conducted in Brazil ⁶⁹. High mortality rates could be associated with several factors, including a low mean PaO2:FiO2 ratio and overloaded public health systems in countries with limited resources, such as Brazil 69 and as well as glucocorticoid dose, initiation, and duration of therapy ^{70,71}. In addition, the precise threshold at which a patient should be treated with glucocorticoids, that is to avoid the manifestation of adverse effects associated with comorbidities and inefficient clearance of SARS-CoV-2, remains unclear 72. However, a delayed start of glucocorticoid therapy could result in a lack of response due to patients reaching a point of no return, as suggested previously by our research group with regards to scorpion poisoning, which triggers a sterile inflammatory process ³. On the other hand, considering that Covid-19 is a non-sterile hyperinflammatory disease, the administration of glucocorticoids is more effective after the initial phase in which hospitalised patients have low or undetectable viral loads ^{18,68}. Our data suggest that SARS-CoV-2 infection activates the glucocorticoidinsensitive release of AA metabolites associated with Covid-19 severity. Hence, lipid mediator production pathways could be important molecular targets for Covid-19 treatment, as suggested by other researchers ⁵³. Accordingly, we suggested that, in order to improve the benefits of glucocorticoid therapy in hospitalized patients, who show

lower or undetectable viral loads, patients should be treated as soon as possible in combination with AA metabolism inhibitors.

CD36 is expressed in several cells ^{73,74}, where it induces Ca⁺⁺ mobilisation, cell signalling, LTB₄ production, and cellular fatty acid uptake ^{75–78}. The maintenance of high free-AA levels in patients with severe/critical glucocorticoid-treated disease may result from the reduction of CD36 on macrophage membranes. Intriguingly, CD36 is a gustatory lipid sensor ⁷⁹, whose deficit in cell membranes may account for the symptoms of ageusia, anosmia, diarrhoea, hyperglycaemia, platelet aggregation, and cardiovascular disturbances experienced by Covid-19 patients ^{75–77}. CD36 is a substrate of matrix metalloproteinase-9 (MMP-9) and disintegrin metalloproteinase domain-containing protein 17 (ADAM17) ^{80,81}. Decreased CD36 expression in Covid-19 patients most likely results from the action of these enzymes. MMP-9 is produced by neutrophils ⁸², induced by TNF-α ⁸³, unaffected by glucocorticoids, and associated with respiratory syndrome in Covid-19 ⁸⁴. ADAM17 has been described as a target for Covid-19 treatment ⁸⁵.

In agreement with previous reports ^{1,34,86,87}, in the present study, high concentrations of IL-6, IL-8, and IL-10 were detected, along with insignificant levels of IL-1β in plasma. In contrast, the inflammatory cytokine TNF-α was found at the lowest concentration in BAL fluid, and insignificant levels were detected in the blood. The low levels of TNF-α production are correlated with the decreased counts of intermediate monocytes in the blood and BAL, which are major sources of this cytokine ⁸⁸. As expected, in the BAL from patients with severe/critical Covid-19, the levels of IL-8, IL-6, IL-1β, TNF-α, and IL-10 were significantly higher compared with the plasma of all participants, or when paired with patients' own plasma. Notably, in BAL, the most abundant cytokine was IL-8, which is produced by neutrophils ⁸⁹, lung macrophages ⁹⁰, and bronchial epithelial cells ¹⁰, and is induced by 5-HETE ³¹ and ACh ¹⁰. Interestingly,

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

BAL fluid from non-Covid-19 patients also presented a high concentration of cytokines that did not differ from that of patients with Covid-19. This suggests that cytokine storms are not a key differential factor in this disease. Contrary to our expectations, glucocorticoids did not alter cytokine production (Table S7). As a result, we suggest that, regardless of whether Covid-19 is treated with glucocorticoids, cross-talk occurs between cytokines, lipid mediators, and ACh, as previously reported ^{2,3,91}. IL-1β induces 11-HETE ⁴⁶; arterial relaxation induced by ACh is mediated by 11-HETE and is inhibited by indomethacin ⁴³. In our studies on scorpion envenomation, ACh release was found to be mediated by PGE₂-induced by IL-1β and inhibited by indomethacin ³. In the present study, comparing AA, 5-HETE, 11-HETE, cytokine, and receptor expression demonstrated the absence of glucocorticoid effects. These results, in addition to the results of other studies from our laboratory ³, suggest that glucocorticoids did not have an effect in our cohort. This was most likely due to the fact that treatment was started late, namely after inflammation has been triggered by infection. In this context, Covid-19 patients could had already reached the point of no return, similar to what has been previously described in scorpion envenomation ³. As predicted by Virgilis and Giovani 92, neurotransmitters are produced in Covid-19. ACh induces mucus secretion, bronchoconstriction, lung inflammation and remodelling ⁹, cardiac dysfunction in scorpionism ³, NETs formation ⁹³, IL-8 release ¹⁰, thrombosis ⁹⁴, and obesity-related severity ⁹⁵. In addition to the nervous system ⁴, ACh is also produced by pulmonary vessels ⁹⁶, airway epithelial cells ⁶, and immune cells ⁵. When binding to anti-inflammatory neural nicotinic receptors induces AA release ⁹⁷, it inhibits nicotine receptors ⁹⁷, which are highly expressed in lungs ⁹⁸. In our cohort, a correlation between the AA and ACh levels and the severity of Covid-19 infection was observed, which was reinforced by the results of our bioinformatics study. Our lung transcriptome

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

re-analyses showed that ACh release cycle genes were activated, including acetylcholinesynaptic release (synaptotagmin 1) and neuronal choline transporter (Solute Carrier Family 5 Member 7, SLC5A7). Accordingly, SLC5A7 gene expression was higher in the lung of patients who died from Covid-19 infection than patients who survived ⁹⁹. Because this gene mediates the translocation of choline into lung epithelial cells 100 and macrophages ¹⁰¹, the production of ACh in BAL may also depend on non-neuronal cells. Indeed, the ACh repressor gene in non-neural cells (RE1 Silencing Transcription Factor) is reduced in the lungs of patients who died of Covid-19 99. The activation of Tlymphocyte EP4 induces the release of ACh ¹⁰², suggesting that AA metabolites contribute to the release of ACh from lung and immune cells. As expected, ACh production in patients with severe/critical disease was found to be inhibited by glucocorticoids, since this drug blocks ACh production by lung epithelial cells ^{103–105}. Patients with Covid-19 (mostly methylprednisolone-treated patients) showed lower plasma levels of choline and higher plasma levels of phosphocholine ³⁷. In addition, a distinct pattern of ACh receptor mRNA expression was found in patients who died of Covid-19 (mainly in the CVL-lengthy hospital stay group). This profile is characterised by low levels of expression of the nicotinic receptor encoded by cholinergic receptor nicotinic alpha 7 subunit gene (CHRNA7) and increased levels of expression of two nicotinic and one muscarinic receptor in deceased-CVL compared to deceased non-Covid-19 patients. These proteins are encoded by the cholinergic nicotinic alpha 3 subunit gene (CHRNA3), the cholinergic nicotinic receptor 5 subunit gene (CHRNA5), and the muscarinic cholinergic receptor 3 gene (CHRM3), respectively. These three upregulated genes were also co-expressed and associated with pulmonary inflammatory disorders 9,106-110. Notably, SARS-CoV-2 spike glycoprotein interacts with the α7 nicotinic

acetylcholine receptor, which may compromise the cholinergic anti-inflammatory pathway¹¹¹.

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

The ACh-nicotinic receptor, encoded by CHRNA7, is expressed in various lung cells and macrophages ¹¹². It displays extensive anti-inflammatory activities, including the inhibition of pro-inflammatory cytokine production ¹¹³, the recruitment of neutrophils ¹¹⁴, and the reduction of CD14 expression in human monocytes ¹¹⁵. The increased degrees of inflammation in the BAL fluid of patients with severe/critical Covid-19 may be associated with the lower levels of anti-inflammatory CHRNA7 expression. However, a reduction in monocyte CD14 may result from high levels of IL-6 production ¹¹⁶, since the levels of CHRNA7 expression were very low. Interestingly, the ACh-M3 receptor in immune cells has been found to be up-regulated by ACh, which mediates its proinflammatory actions, including the production of IL-8 and the recruitment of neutrophils ¹¹⁷. Furthermore, the interaction between ACh and its receptor triggers the AA-derived release of eicosanoids, including 5-HETE ^{97,118,119}. Remarkably, vitamin D modulates the ACh-M3 receptor ¹²⁰, which may explain its beneficial effects in the prevention of Covid-19 ¹²¹. Based on the anti-inflammatory effects of nicotinic receptors and the downregulation of the SARS-CoV-2 receptor ACE2 promoted by nicotine, therapies involving nicotinic receptors have been proposed to treat Covid-19 infection ^{122,123}. In fact, based on these findings, an acetylcholinesterase inhibitor 124,125 and a nicotinic receptor agonist have been tested ^{126,127}. However, recent studies have demonstrated that nicotine and smoking increase ACE2 receptor density 128,129, and that the potential beneficial effects of nicotine were restricted to a small group of individuals ¹³⁰. Our findings provide a warning that precautions should be taken when considering the therapeutic use of nicotinic agonists, since patients with severe/critical Covid-19 were found to release high amounts of ACh, in addition to showing increased levels of M3-

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

receptor expression. Due to the antiviral and anti-inflammatory effects of AA, it has been proposed to treat Covid-19 patients ⁶⁰. Nevertheless, AA may be not be an adequate therapeutic target, based on both our findings and previous studies ¹³¹, which have shown that AA can favour hyperinflammation and lethality in Covid-19 infection. In conclusion, ACh, AA, 5-HETE, and 11-HETE mediate the innate immune response to SARS-CoV-2 and may define the outcome of infection. Covid-19 severity can be associated with disruption of homeostatic lipidome and metabolic alterations and this phenomenon may be influenced by comorbidities/risk factors related to the infection. Our findings demonstrated that (i) high plasma levels of ACh and lipid mediators positively correlated with Covid-19 severity; and (ii) only hypertension and/or age were confounding variables for analyzing the association of high plasma levels of AA, 5-HETE, and ACh with disease severity (Table S7). Similarly, the correlation between altered plasma profile of lipid mediators and Covid-19 severity is associated with selective comorbidities - mainly high body mass index (BMI) - but poorly associated with gender, advanced age, and diabetes. However, the correlation between altered AA and/or 5-HETE levels and disease severity is associated with male gender, hypertension, and heart disease, but not BMI⁵³. We also examined whether glucocorticoid-therapy interfered with the potential effect of some confounding variables on the correlation between high ACh levels and Covid-19 severity in severe/critical patients. Despite the relatively underrepresented samples from non-glucocorticoid treated patients, no confounding variable significantly affected the correlation between plasma and BAL ACh levels and Covid-19 severity in severe/critical patients treated or not with glucocorticoids (Table S8). The altered plasma and BAL levels of the lipid mediators AA, 5-HETE, and 11-HETE in severe/critical patients were associated with the disease severity but not with the confounding variables

tested (Table S9). Altogether, the findings here reported suggest that age and/or hypertension are significant confounding variables for analyzing the association between increased levels of cholinergic and lipid mediators and Covid-19 severity. Also, the confounding variables tested probably did not modify the inhibitory action of glucocorticoids on plasma and BAL ACh levels in severe/critical patients.

To the best of our knowledge, this study is the first to demonstrate that the lung inflammatory process and poor outcomes of patients with Covid-19 infection are associated with high levels of lipid mediators and ACh, produced via a partially glucocorticoid-insensitive pathway. Glucocorticoid therapy was found to lower only the levels of ACh. Thus, to improve the benefits of glucocorticoid therapy, we suggest that treatment in hospitalised patients be started early and be preferentially administered to patients with low or undetectable viral loads and harmful lung inflammation in combination with AA metabolism inhibitors.

Conclusions

We demonstrate for the first time that the lung inflammatory process and worse outcomes in Covid-19 are associated with lipid mediators and ACh, which are produced through a partially glucocorticoid-insensitive pathway. To improve the benefits of glucocorticoid therapy, we suggest that it should be started early in severe/critical hospitalized patients and in combination with AA metabolism inhibitors.

References

743

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
- novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
- 746 2. Esser-von Bieren J. Immune-regulation and -functions of eicosanoid lipid
- 747 mediators. Biol. Chem. 2017;
- Reis M, Rodrigues F, Lautherbach N, et al. Interleukin-1 receptor-induced PGE2
- production controls acetylcholine-mediated cardiac dysfunction and mortality
- during scorpion envenomation. Nat Commun 2020;11(1).
- 751 4. McGovern AE, Mazzone SB. Neural regulation of inflammation in the airways
- and lungs. Auton Neurosci Basic Clin 2014;
- 753 5. Wessler I, Kirkpatrick CJ. Cholinergic signaling controls immune functions and
- promotes homeostasis. Int. Immunopharmacol. 2020;
- 755 6. Proskocil BJ, Sekhon HS, Jia Y, et al. Acetylcholine is an autocrine or paracrine
- hormone synthesized and secreted by airway bronchial epithelial cells.
- 757 Endocrinology 2004;
- 758 7. Chang EH, Chavan SS, Pavlov VA. Cholinergic control of inflammation,
- metabolic dysfunction, and cognitive impairment in obesity-associated disorders:
- Mechanisms and novel therapeutic opportunities. Front. Neurosci. 2019:
- Roy A, Guatimosim S, Prado VF, Gros R, Prado MAM. Cholinergic activity as a
- new target in diseases of the heart. Mol Med 2014;
- 763 9. Kistemaker LEM, Gosens R. Acetylcholine beyond bronchoconstriction: roles in
- inflammation and remodeling. Trends Pharmacol Sci 2015;36(3):164–71.
- 765 10. Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8
- in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J
- 767 Pharmacol 2008;

- 768 11. Shields MD, Riedler J. Bronchoalveolar lavage and tracheal aspirate for
- assessing airway inflammation in children. Am J Respir Crit Care Med
- 770 2000;162(2 II).
- 771 12. Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: An
- open platform for biomedical image analysis. Mol Reprod Dev 2015;82(7–
- 773 8):518–29.
- 774 13. Sorgi CA, Peti APF, Petta T, et al. Data descriptor: Comprehensive high-
- resolution multiple-reaction monitoring mass spectrometry for targeted
- eicosanoid assays. Sci Data 2018;
- 777 14. Chambers MC, MacLean B, Burke R, et al. A cross-platform toolkit for mass
- spectrometry and proteomics. Nat. Biotechnol. 2012;
- 779 15. Yu T, Park Y, Johnson JM, Jones DP. apLCMS-adaptive processing of high-
- resolution LC/MS data. Bioinformatics 2009;
- 781 16. Li S, Park Y, Duraisingham S, et al. Predicting Network Activity from High
- 782 Throughput Metabolomics. PLoS Comput Biol 2013;
- 783 17. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of
- immune perturbations associated with severe COVID-19. Sci Immunol 2020;
- 785 18. Desai N, Neyaz A, Szabolcs A, et al. Temporal and spatial heterogeneity of host
- response to SARS-CoV-2 pulmonary infection. Nat Commun [Internet]
- 787 2020;11(1):6319. Available from: http://www.nature.com/articles/s41467-020-
- 788 20139-7
- 789 19. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene
- 790 expression and hybridization array data repository. Nucleic Acids Res 2002;
- 791 20. Russo PST, Ferreira GR, Cardozo LE, et al. CEMiTool: A Bioconductor package
- for performing comprehensive modular co-expression analyses. BMC

- 793 Bioinformatics 2018;
- 794 21. Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase.
- 795 Nucleic Acids Res 2020;
- 796 22. Love MI, Huber W, Anders S. Moderated estimation of fold change and
- 797 dispersion for RNA-seq data with DESeq2. Genome Biol 2014;
- 798 23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
- 799 Powerful Approach to Multiple Testing. J R Stat Soc Ser B 1995;
- 800 Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. 24.
- 801 BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006;
- 802 25. Csardi G, Nepusz T. The igraph software package for complex network research.
- 803 InterJournal Complex Syst 2006;
- 804 Maintainer MB, Bojanowski M. Package "intergraph" Type Package Title 26.
- 805 Coercion Routines for Network Data Objects. 2016;
- 806 27. Tyner S, Briatte F, Hofmann H. Network visualization with ggplot2. R J
- 807 2017;9(1):27–59.
- 808 28. Taylor R. Interpretation of the Correlation Coefficient: A Basic Review. J
- 809 Diagnostic Med Sonogr 1990;
- 810 29. Abreu-Filho PG, Tarragô AM, Costa AG, et al. Plasma Eicosanoid Profile in
- 811 Plasmodium vivax Malaria: Clinical Analysis and Impacts of Self-Medication.
- 812 Front Immunol 2019;
- 813 30. Fukunaga Y, Mine Y, Yoshikawa S, Takeuchi T, Hata F, Yagasaki O. Role of
- 814 prostacyclin in acetylcholine release from myenteric plexus of guinea-pig ileum.
- 815 Eur J Pharmacol 1993;233(2-3):237-42.
- 816 31. Clark SR, Guy CJ, Scurr MJ, et al. Esterified eicosanoids are acutely generated
- 817 by 5-lipoxygenase in primary human neutrophils and in human and murine

- 818 infection. Blood 2011;
- 819 32. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and
- moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–9.
- 821 33. Knight DS, Kotecha T, Razvi Y, et al. COVID-19: Myocardial injury in
- 822 survivors. Circulation. 2020;
- 823 34. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine
- signature predicts COVID-19 severity and survival. Nat Med 2020;
- 825 35. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-
- 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;
- 827 36. Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview:
- Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-
- 829 CoV-2 Infection Explains Severe Outcomes in COVID-19. Front. Immunol.
- 830 2020;
- 831 37. Shen B, Yi X, Sun Y, et al. Proteomic and Metabolomic Characterization of
- 832 COVID-19 Patient Sera. Cell 2020;
- 833 38. Delafiori J, Claudio Navarro L, Focaccia Siciliano R, et al. Covid-19 automated
- diagnosis and risk assessment through Metabolomics and Machine-Learning.
- 835 2020.
- 836 39. Bittleman DB, Casale TB. 5-Hydroxyeicosatetraenoic acid (HETE)-induced
- neutrophil transcellular migration is dependent upon enantiomeric structure. Am
- 838 J Respir Cell Mol Biol 1995;12(3):260–7.
- 839 40. Harder DR. Pressure-induced myogenic activation of cat cerebral arteries is
- dependent on intact endothelium. Circ Res 1987;
- 841 41. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of
- 842 COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;

- 843 Kita Y, Takahashi T, Uozumi N, Nallan L, Gelb MH, Shimizu T. Pathway-42.
- 844 oriented profiling of lipid mediators in macrophages. Biochem Biophys Res
- 845 Commun 2005;
- 846 Gauthier KM, Goldman DH, Aggarwal NT, Chawengsub Y, Falck JR, Campbell 43.
- 847 WB. Role of arachidonic acid lipoxygenase metabolites in acetylcholine-induced
- 848 relaxations of mouse arteries. Am J Physiol - Hear Circ Physiol 2011;
- 849 44. Rauzi F, Kirkby NS, Edin ML, et al. Aspirin inhibits the production of
- 850 proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. FASEB J 2016;
- 851 45. Berna N, Arnould T, Remacle J, Michiels C. Hypoxia-induced increase in
- 852 intracellular calcium concentration in endothelial cells: Role of the Na+-glucose
- 853 cotransporter. J Cell Biochem 2002;
- 854 López S, Vila L, Breviario F, de Castellarnau C. Interleukin-1 increases 15-46.
- 855 hydroxyeicosatetraenoic acid formation in cultured human endothelial cells.
- 856 Biochim Biophys Acta (BBA)/Lipids Lipid Metab 1993;
- 857 47. Metz SA, Murphy RC, Fujimoto W, . Effects on glucose-induced insulin
- 858 secretion of lipoxygenase-derived metabolites of arachidonic acid. Diabetes
- 859 1984;33(2):119-24.
- 860 48. Hosoi T, Koguchi Y, Sugikawa E, et al. Identification of a novel human
- 861 eicosanoid receptor coupled to Gi/o. J Biol Chem 2002;
- 49. 862 Powell WS, Rokach J, ., . The eosinophil chemoattractant 5-oxo-ETE and the
- 863 OXE receptor. Prog. Lipid Res. 2013;
- 864 50. Powell WS, Rokach J. Targeting the OXE receptor as a potential novel therapy
- 865 for asthma. Biochem Pharmacol 2020;179:113930.
- 866 51. Schwarz B, Sharma L, Roberts L, et al. Cutting Edge: Severe SARS-CoV-2
- 867 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in

868 Dysregulation of Eicosanoid Immune Mediators. J Immunol [Internet] 869 2020;ji2001025. Available from: 870 http://www.jimmunol.org/content/early/2020/12/04/jimmunol.2001025.abstract 871 Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: A review. J. 52. 872 Adv. Res. 2018; 873 53. Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in humans 874 is defined by a shift in the serum lipidome resulting in dysregulation of 875 eicosanoid immune mediators. Res Sq 2020; 876 54. Nienhold R, Ciani Y, Koelzer VH, et al. Two distinct immunopathological 877 profiles in autopsy lungs of COVID-19. Nat Commun [Internet] 878 2020;11(1):5086. Available from: https://doi.org/10.1038/s41467-020-18854-2 879 Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical 55. 880 illness in Covid-19. Nature [Internet] 2020; Available from: 881 https://doi.org/10.1038/s41586-020-03065-y 882 56. Taha AY. Linoleic acid-good or bad for the brain? npj Sci. Food. 2020; 883 Kohn A, Gitelman J, Inbar M. Unsaturated free fatty acids inactivate animal 57. 884 enveloped viruses. Arch Virol 1980; 885 58. Das UN. Arachidonic acid and other unsaturated fatty acids and some of their 886 metabolites function as endogenous antimicrobial molecules: A review. J. Adv. 887 Res. 2018; 888 59. Chandrasekharan JA, Sharma-Walia N. Arachidonic acid derived lipid mediators 889 influence Kaposi's sarcoma-associated herpesvirus infection and pathogenesis. 890 Front. Microbiol. 2019; 891 60. Das UN. Bioactive Lipids in COVID-19-Further Evidence. Arch Med Res 2020;

Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II

892

61.

phospholipase A2 production by blocking mRNA synthesis and post-893 894 transcriptional expression. J Biol Chem 1990; 895 62. Kobza Black A, Greaves M, Hensby C. The effect of systemic prednisolone on 896 arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous 897 inflammation. Br J Clin Pharmacol 1982; 898 63. Hu X, Cifarelli V, Sun S, Kuda O, Abumrad NA, Su X. Major role of adipocyte 899 prostaglandin E2 in lipolysis-induced macrophage recruitment. J Lipid Res 2016; 900 Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA, Graham MF. 64. 901 Linoleic acid induces interleukin-8 production by Crohn's human intestinal 902 smooth muscle cells via arachidonic acid metabolites. Am J Physiol -903 Gastrointest Liver Physiol 2004; 904 Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate 65. 905 endocannabinoid signaling in the nervous system. Chem Rev 2008;108(5):1687– 906 707. 907 Grant RA, Morales-Nebreda L, Markov NS, et al. Alveolitis in severe SARS-66. 908 CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar 909 macrophages and T cells. bioRxiv 2020; 910 67. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid 911 metabolism toward endocannabinoid synthesis: A non-genomic anti-912 inflammatory switch. Eur. J. Pharmacol. 2008; 913 68. The RECOVERY Collaborative G. Dexamethasone in Hospitalized Patients with 914 Covid-19 — Preliminary Report. N Engl J Med 2020; 915 69. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days 916 Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory 917 Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

JAMA - J Am Med Assoc 2020;

918

- 70. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The
- 920 Current Evidence and Treatment Strategies. Front. Immunol. 2020;
- 921 71. Ye Q, Wang B, Mao J, . The pathogenesis and treatment of the 'Cytokine
- 922 Storm' in COVID-19.' J. Infect. 2020;
- 923 72. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope
- 924 during the Pandemic. JAMA J. Am. Med. Assoc. 2020;
- 925 73. Noushmehr H, D'Amico E, Farilla L, et al. Fatty acid translocase (FAT/CD36) is
- localized on insulin-containing granules in human pancreatic β -cells and
- mediates fatty acid effects on insulin secretion. Diabetes 2005;
- 928 74. Glatz JFC, Luiken J. From fat to FAT (CD36/SR-B2): Understanding the
- regulation of cellular fatty acid uptake. Biochimie. 2017;
- 930 75. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor
- involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J.
- 932 Clin. Invest. 2001;
- 933 76. Glatz JFC, Luiken JJFP, Bonen A. Membrane fatty acid transporters as regulators
- of lipid metabolism: Implications for metabolic disease. Physiol. Rev. 2010;
- 935 77. Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36
- and importance of fatty acid signal transduction in fat metabolism. Annu. Rev.
- 937 Nutr. 2014;
- 938 78. Zoccal KF, Gardinassi LG, Sorgi CA, et al. CD36 shunts eicosanoid metabolism
- to repress CD14 Licensed interleukin-1β release and inflammation. Front
- 940 Immunol 2018;
- 941 79. Khan NA, Besnard P. Oro-sensory perception of dietary lipids: New insights into
- the fat taste transduction. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2009;

- Deleon-Pennell KY, Tian Y, Zhang B, et al. CD36 Is a Matrix Metalloproteinase-943 80.
- 944 9 Substrate That Stimulates Neutrophil Apoptosis and Removal during Cardiac
- 945 Remodeling. Circ Cardiovasc Genet 2016;
- 946 81. Novak ML, Thorp EB. Shedding light on impaired efferocytosis and
- 947 nonresolving inflammation. Circ. Res. 2013;
- 948 82. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-
- 949 derived matrix metalloproteinase-9 is increased in severe asthma and poorly
- 950 inhibited by glucocorticoids. J Allergy Clin Immunol 2003;
- 951 83. Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of
- 952 MMP-9 in normal human bronchial epithelial cells by TNF-α via NF-κB-
- 953 mediated pathway. Am J Physiol - Lung Cell Mol Physiol 2001;
- 954 Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating 84.
- 955 MMP-9 in COVID-19 patients with respiratory failure: MMP-9 and respiratory
- 956 failure in COVID-19. J. Infect. 2020;
- 957 85. Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect
- 958 on COVID-19. Nephrol Dial Transplant 2020;
- 959 86. Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID-19
- 960 immune signature includes associations with poor prognosis. Nat Med 2020:
- 961 87. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-
- 962 1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight
- 963 2020;
- 964 88. Belge K-U, Dayyani F, Horelt A, et al. The Proinflammatory CD14 + CD16 +
- 965 DR ++ Monocytes Are a Major Source of TNF. J Immunol 2002;
- 966 89. Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): The
- 967 major neutrophil chemotactic factor in the lung. Exp Lung Res 1991;

- 968 90. Kunkel TA, Bebenek K, McClary J. Efficient site-directed mutagenesis using
- 969 uracil-containing DNA. Methods Enzymol 1991;
- 970 91. Zoccal KF, Sorgi CA, Hori JI, et al. Opposing roles of LTB4 and PGE2 in
- 971 regulating the inflammasome-dependent scorpion venom-induced mortality. Nat
- 972 Commun 2016;
- 973 92. De Virgiliis F, Di Giovanni S. Lung innervation in the eye of a cytokine storm:
- 974 neuroimmune interactions and COVID-19. Nat Rev Neurol 2020;
- 975 93. Carmona-Rivera C, Purmalek MM, Moore E, et al. A role for muscarinic
- 976 receptors in neutrophil extracellular trap formation and levamisole-induced
- 977 autoimmunity. JCI Insight 2017;
- 978 94. do Espírito Santo DA, Lemos ACB, Miranda CH, . In vivo demonstration of
- 979 microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 2020;
- 980 95. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as
- emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs. 2008;
- 982 96. Cavallotti C, Bruzzone P, Mancone M, Leali FMT. Distribution of
- acetylcholinesterase and cholineacetyl-transferase activities in coronary vessels
- of younger and older adults. Geriatr Gerontol Int 2004;
- 985 97. Vijayaraghavan S, Huang B, Blumenthal EM, Berg DK. Arachidonic acid as a
- possible negative feedback inhibitor of nicotinic acetylcholine receptors on
- 987 neurons. J Neurosci 1995;
- 988 98. Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a
- murine model of acute lung injury. Inflammation 2011;
- 990 99. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to
- 991 SARS-CoV-2 Drives Development of COVID-19. Cell 2020;
- 992 100. Horiguchi K, Horiguchi S, Yamashita N, et al. Expression of SLURP-1, an

993 endogenous α7 nicotinic acetylcholine receptor allosteric ligand, in murine 994 bronchial epithelial cells. J Neurosci Res 2009; 995 101. Schirmer SU, Eckhardt I, Lau H, et al. The cholinergic system in rat testis is of 996 non-neuronal origin. Reproduction 2011; 997 Suenaga A, Fujii T, Ogawa H, et al. Up-regulation of lymphocytic cholinergic 998 activity by ONO-4819, a selective prostaglandin EP4 receptor agonist, in MOLT-999 3 human leukemic T cells. Vascul Pharmacol 2004; 1000 103. Reinheimer T, Münch M, Bittinger F, Racké K, Kirkpatrick CJ, Wessler I. 1001 Glucocorticoids mediate reduction of epithelial acetylcholine content in the 1002 airways of rats and humans. Eur J Pharmacol 1998; 1003 104. Gross I, Ballard PL, Ballard RA, Jones CT, Wilson CM. Corticosteroid 1004 stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung: 1005 Evidence for de novo protein synthesis mediated by glucocorticoid receptors. 1006 Endocrinology 1983; 1007 Nakamura T, Fujiwara R, Ishiguro N, et al. Involvement of choline transporter-105. 1008 like proteins, CTL1 and CTL2, in glucocorticoid-induced acceleration of 1009 phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull 1010 2010; 1011 Wilk JB, Shrine NRG, Loehr LR, et al. Genome-wide association studies identify 1012 CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir 1013 Crit Care Med 2012; 1014 107. Lam DCL, Luo SY, Fu KH, et al. Nicotinic acetylcholine receptor expression in 1015 human airway correlates with lung function. Am J Physiol - Lung Cell Mol 1016 Physiol 2016; 1017 Oenema TA, Kolahian S, Nanninga JE, et al. Pro-inflammatory mechanisms of

1018 muscarinic receptor stimulation in airway smooth muscle. Respir Res 2010; 1019 109. Yamada M, Ichinose M. The cholinergic pathways in inflammation: A potential 1020 pharmacotherapeutic target for COPD. Front. Pharmacol. 2018; 1021 Fadason T, Schierding W, Lumley T, O'Sullivan JM. Chromatin interactions and 1022 expression quantitative trait loci reveal genetic drivers of multimorbidities. Nat 1023 Commun 2018;9(1):5198. 1024 111. Lagoumintzis G, Chasapis CT, Alexandris N, et al. COVID-19 and Cholinergic 1025 Anti-inflammatory Pathway: In silico Identification of an 1026 Interaction between α7 Nicotinic Acetylcholine Receptor and the Cryptic 1027 Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins. bioRxiv 1028 [Internet] 2020;2020.08.20.259747. Available from: 1029 http://biorxiv.org/content/early/2020/08/21/2020.08.20.259747.abstract 1030 112. Gahring LC, Myers EJ, Dunn DM, Weiss RB, Rogers SW. Nicotinic alpha 7 1031 receptor expression and modulation of the lung epithelial response to 1032 lipopolysaccharide. PLoS One 2017; 1033 Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor α7 subunit is 113. 1034 an essential regulator of inflammation. Nature 2003;421(6921):384-8. 1035 Pinheiro NM, Santana FPR, Almeida RR, et al. Acute lung injury is reduced by 1036 the a7nAChR agonist PNU-282987 through changes in the macrophage profile. 1037 FASEB J 2017; 1038 115. Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N. 1039 Stimulation of α7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like 1040 receptor 4 expression in human monocytes. Shock 2006; 1041 Hasday JD, Dubin W, Mongovin S, et al. Bronchoalveolar macrophage CD14 116. 1042 expression: Shift between membrane- associated and soluble pools. Am J Physiol

- Lung Cell Mol Physiol 1997;
- 1044 117. Gori S, Alcain J, Vanzulli S, et al. Acetylcholine-treated murine dendritic cells
- promote inflammatory lung injury. PLoS One 2019;
- 1046 118. Edwards JM, McCarthy CG, Wenceslau CF. The Obligatory Role of the
- 1047 Acetylcholine-Induced Endothelium-Dependent Contraction in Hypertension:
- 1048 Can Arachidonic Acid Resolve this Inflammation? Curr Pharm Des 2020;
- 1049 119. Radu BM, Osculati AMM, Suku E, et al. All muscarinic acetylcholine receptors
- 1050 (M1-M5) are expressed in murine brain microvascular endothelium. Sci Rep
- 1051 2017;
- 1052 120. Kumar PT, Antony S, Nandhu MS, Sadanandan J, Naijil G, Paulose CS. Vitamin
- D3 restores altered cholinergic and insulin receptor expression in the cerebral
- 1054 cortex and muscarinic M3 receptor expression in pancreatic islets of
- streptozotocin induced diabetic rats. J Nutr Biochem 2011;
- 1056 121. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and
- severity. J. Infect. Public Health. 2020;
- 1058 122. CHANGEUX jean-pierre, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis
- for Covid-19 with preventive and therapeutic implications. Qeios 2020;
- 1060 123. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the
- renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018;
- 1062 124. Nct. Pyridostigmine in Severe SARS-CoV-2 Infection.
- https://clinicaltrials.gov/show/NCT04343963 2020;
- 1064 125. Ahmed H O. COVID-19: Targeting the cytokine storm via cholinergic anti-
- inflammatory (Pyridostigmine). Int J Clin Virol 2020;
- 1066 126. Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, et al. Cytokine Release
- Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.

- 1068 Front Immunol 2020;
- 1069 127. ahir AMOURA FT. Efficacy of Nicotine in Preventing COVID-19 Infection in
- 1070 Caregivers (NICOVID-PREV). Natl Libr Med 2020;2:1–8.
- 1071 Smith JC, Sausville EL, Girish V, et al. Cigarette Smoke Exposure and 128.
- 1072 Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor
- 1073 ACE2 in the Respiratory Tract. Dev Cell 2020;
- 1074 129. Leung JM, Leung JM, Yang CX, Sin DD, Sin DD. COVID-19 and nicotine as a
- 1075 mediator of ACE-2. Eur. Respir. J. 2020;
- 1076 130. Zureik M, Baricault B, Vabre C, et al. Nicotine-replacement therapy as a
- 1077 surrogate of smoking and the risk of hospitalization with Covid-19 and all-cause
- 1078 mortality a nationwide observational cohort study in France. medrxiv 2020;
- 1079 Margină D, Ungurianu A, Purdel C, et al. Chronic inflammation in the context of
- 1080 everyday life: Dietary changes as mitigating factors. Int. J. Environ. Res. Public
- 1081 Health. 2020;
- 1082 Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and 132.
- 1083 inflammatory responses in severe COVID-19 patients. Science (80-) 2020;
- 1084 133. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory
- 1085 syndrome coronavirus 2 reactivation. J Infect 2020;
- 1086 Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected
- 1087 with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China:
- 1088 Retrospective case series. BMJ 2020;
- 1089 135. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes
- 1090 of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy
- 1091 Region, Italy. JAMA - J Am Med Assoc 2020;
- 1092 Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set

- 1093 for COVID-19 clinical research. Lancet Infect. Dis. 2020;
- 1094 137. Office WHOEMR. Updated clinical management guideline for COVID-19.
- 1095 Wkly. Epidemiol. Monit. 2020;
- 1096 Rauch A, Labreuche J, Lassalle F, et al. Coagulation biomarkers are independent 138.
- 1097 predictors of increased oxygen requirements in COVID-19. J Thromb Haemost
- 1098 2020;
- 139. 1099 Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising
- 1100 biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020;
- 1101 140. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
- 1102 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-
- 1103 19 in the New York City Area. JAMA [Internet] 2020;323(20):2052–9. Available
- 1104 from: https://doi.org/10.1001/jama.2020.6775
- 1105 141. Thomas T, Stefanoni D, Reisz J, et al. COVID-19 infection results in alterations
- 1106 of the kynurenine pathway and fatty acid metabolism that correlate with IL-6
- 1107 levels and renal status. medRxiv Prepr Serv Heal Sci 2020;
- 1108 Moolamalla STR, Chauhan R, Priyakumar D, Vinod PK. Host metabolic 142.
- 1109 reprogramming in response to SARS-Cov-2 infection. bioRxiv 2020;
- 1110 Soliman S, Faris MAIE, Ratemi Z, Halwani R. Switching Host Metabolism as an
- 1111 Approach to Dampen SARS-CoV-2 Infection. Ann. Nutr. Metab. 2020;
- 1112 Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HWL. 144.
- 1113 Differential cytokine expression in human blood monocyte subpopulations: A
- 1114 polymerase chain reaction analysis. Blood 1996;
- 1115 145. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune
- 1116 Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host
- 1117 Microbe 2020;

1118 146. Lamontagne F, Brower R, Meade M. Corticosteroid therapy in acute respiratory 1119 distress syndrome. CMAJ. 2013; 1120 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support 147. 1121 corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 1122 1123 Acknowledgements 1124 The authors thankfully acknowledge Innovation and Technology Park (Supera), the 1125 healthy-participants joining as controls and the positive COVID-19 patients as well as 1126 their families. We grieve for all patients who lost their lives as a result of this pandemic, 1127 including those who provided us with samples to be able to answer scientific questions 1128 and contribute to humanity's eradication of this disease. We also thank Fabiana Rossetto

work through Hospital Santa Casa de Misericórdia in Ribeirão Preto and Hospital São

Paulo in Ribeirão Preto. We are grateful for the indispensable contribution of the Ribeirão

Preto Municipal Health Department and the employees of the Serviço de Análises

Clínicas (SAC) of the Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP. We

also thank Professors Victor Hugo Aquino Quintana, Ph.D., Márcia Regina von Zeska

Kress, Ph.D., and Marcia Eliana da Silva Ferreira, Ph.D. for sharing the BSL2 viral

laboratory.

1129

1130

1131

1133

1134

1135

1136

1137

1138

1139

1140

Additional Information

1141

1142 Extended data available in Supplementary Appendixes: 1143 Supplementary Appendix I - Pathways and list of corresponding genes related to 1144 acetylcholine and arachidonic acid observed in Reactome pathways and Covid-19 1145 biomarkers. 1146 1147 Supplementary Appendix II - Report of CEMITool results for the gene co-1148 expression modular analysis of lung samples from biopsies of Covid-19 and non-1149 Covid-19 patients. 1150 1151 Supplementary Appendix III - Differential gene expression analysis results 1152 between Covid-19-death groups (CV, NCV, CVL and CVH) and Covid-19 1153 samples from patients who underwent glucocorticoid treatment (GC) and not 1154 (non-GC). 1155 1156 Supplementary Appendix IV - Betweenness and degree values of genes from 1157 biological network constructed based on the principal co-expression module M1. 1158 1159 **Funding** 1160 1161 Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP): 1162 #2020/05207-6, #2014/07125-6 and #2015/00658-1 for **L.H.F**.; #2020/08534-8 for 1163 **M.M.P.**; #2018/22667-0 for **C.O.S.S.**; #2020/05270-0 for **V.D.B**. Additional support was provided by the National Council for Scientific and Technological Development (CNPq), the Coordination for the Improvement of Higher Educational Personnel (CAPES-Finance Code 001)), and Pró-Reitora de Pesquisa da Universidade de São Paulo, grant-USP-VIDA.

Conflict of Interest Statement

The authors declare that this research was performed without conflicts of interest or commercial or financial gains.

Legends of main figures

Figure 1. Metabolomic and lipidomic analysis revealed increased levels of circulating fatty acids, arachidonic acid (AA), 5-HETE and 11-HETE in patients with Covid-19.

Plasma samples were collected from healthy-participants (n=20) and patients with asymptomatic-to-mild (n=10), moderate (n=12), severe (n=16), or critical (n=13) disease. (A) A Manhattan plot for the differential abundance of metabolite features in different groups of patients with Covid-19 and healthy participants (false discovery rate (FDR) of 595, adjusted P<0.05, above the dashed line) and (B, left panel) metabolic pathway enrichment of significant metabolite features based on data from untargeted mass spectrometry. Differential abundance was calculated using the *limma* package for R, and FDR was controlled using the Benjamini-Hochberg method. Mummichog software v2.3.3 was used for pathway enrichment analysis. (B, right panel) Schematic illustration of the metabolic pathways involved in the production of hydroxyeicosatetraenoic acids (HETEs), such as 5-HETE and 11-HETE, from arachidonic (AA) and linoleic acid metabolism, which discriminate the severity of Covid-19. (C-E) Plasma metabolomics

indicating an increase in free fatty acids in Covid-19. Plasma obtained from healthy participants (n=18) and patients with asymptomatic-to-mild (n=10), moderate (n=12), severe (n=14), or critical (n=16) disease (F-H) was subjected to lipidomics analysis using targeted mass spectrometry, confirming the elevation of AA, 5-HETE and 11-HETE, according to the severity of Covid-19. Data are expressed as the mean ± SEM. Differences in (C-H) were considered significant at P<0.05 according to Kruskal–Wallis analysis followed by Dunn's posttest, and specific P-values are shown in each figure.

Figure 2. Systemic markers of inflammation determined Covid-19 severity.

(A-F) Total and differential leukocyte counts in peripheral blood from healthy-participants (n=17) and from patients with asymptomatic-to-mild (n=10), moderate (n=12), severe (n=16) or critical (n=13) disease showed that Covid-19 modified the numbers of distinct leukocyte populations. (G-H) Flow cytometry analysis of CD14+HLA-DR circulating monocytes by t-distributed stochastic neighbour embedding indicated reduced (G) CD14 and (H) CD36 mean fluorescence intensity in asymptomatic-to-mild (n=16), moderate (n=15), severe (n=35), and critical (n=20) Covid-19 patients compared to healthy participants (n=12). (I) Soluble CD14 (sCD14), as determined by ELISA) in healthy participants (n=12), asymptomatic-to-mild (n=12), moderate (n=13), severe (n=15), and critical (n=15) patients, showed increases only in samples from critical Covid-19 patients. (J-L) Classical, intermediate, and nonclassical monocytes determined by flow cytometry analyses of CD14, CD16 and HLA-DR expression in blood cells from healthy participants (n=12), asymptomatic-to-mild (n=16), moderate (n=15), severe (n=35), and critical (n=20) Covid-19 patients revealed a decrease in intermediate monocytes in Covid-19. (M-Q) Cytokines (IL-8, IL-6, IL-1β, TNF and IL-10) quantified

in plasma using a Cytometric Bead Array (CBA) of healthy volunteers (n=35), asymptomatic-to-mild (n=29), moderate (n=35), severe (n=42), and critical (n=21) patients demonstrated a distinct cytokine profile according to disease severity. Data are expressed as the mean ± SEM, and differences between groups were calculated using Kruskal–Wallis with Dunn's multiple comparison post-tests. The specific P-values are displayed in each figure. Differences were considered significant at P<0.05.

Figure 3. Altered production of lipid mediators and cellular infiltrates in the lungs drove the local response to SARS-CoV-2 infection.

BAL was collected from intubated patients with severe/critical confirmed Covid-19 diagnosis and from intubated patients without SARS-CoV-2 infection, which are labelled as Covid-19 and non-Covid-19, respectively. Data from untargeted mass spectrometry demonstrated (A) differential abundance of metabolite features comparing Covid-19 and non-Covid-19 participants (Manhattan plot, 595 at FDR adjusted P<0.05, above the dashed line) and (B) metabolic pathway enrichment of significant metabolite features. Differential abundance was calculated using the *limma* package for R, and the false discovery rate was controlled using the Benjamini-Hochberg method; Covid-19 (n=26) and non-Covid-19 (n=12). Mummichog software v2.3.3 was used for lipid pathway enrichment analysis. (C) Lipid mediators derived from arachidonic acid (AA) metabolism by lipoxygenase (LOX) or cyclooxygenase (COX) in both Covid-19 (n=19) and non-Covid-19 (n=11) samples, as determined by target mass spectrometry, showed a significant increase in 5-HETE and 11-HETE in Covid-19. (D) Total leukocytes in BAL fluid (left panel) and a representative image of Romanowsky staining in these cells (right panel) used for (E) identification of specific cellular populations in Covid-19 (n=23) and

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

non-Covid-19 (n=11) patients showed a similar profile of infiltrating cells. (F) Cytokine concentrations in BAL from intubated Covid-19 patients (n=23) and non-Covid-19 participants (n=11) also revealed a similar profile. (G, H) Classical and intermediate monocytes determined by flow cytometry analyses of CD14, CD16 and HLA-DR expression in BAL cells from Covid-19 (n=10) and non-Covid-19 (n=11) patients demonstrate that both populations are decreased in Covid-19. (I) CD14 and (J) CD36 mean fluorescence intensity (MFI) of CD14⁺HLA-DR gated BAL monocytes is decreased in Covid-19 (n=10) compared to non-Covid-19 (n=11) patients. 5-HPETE: 5hydroperoxyeicosatetraenoic acid, LTA4: leukotriene A4, LTA4 hydrolase: leukotriene A4 hydrolase, LTB₄: leukotriene B₄, 6-trans LTB₄: 6-trans leukotriene B₄, 5-HETE: 5hydroxyeicosatetraenoic acid, 11-HETE: 11-hydroxyeicosatetraenoic acid, 12-HETE: 12-hydroxyeicosatetraenoic acid, 15-HETE: 15-hydroxyeicosatetraenoic acid, 5-oxo-HETE: 5-oxoeicosatetraenoic acid, 12-oxo-ETE: 12-oxoeicosatetraenoic acid, 15-oxo-HETE: 15-oxoeicosatetraenoic acid, PGH₂: prostaglandin H₂, PGE₂: prostaglandin E₂, PGD₂: prostaglandin D₂, TXB₂: thromboxane B, TX synthase: thromboxane. Data are expressed as the mean \pm SEM. Differences between groups were calculated using the Mann-Whitney test, and specific P-values are shown in the figure. Differences were considered significant at P<0.05.

Figure 4. Severe and critical phases of Covid-19 correlated with increased systemic and lung acetylcholine and lipid mediators, but only ACh was diminished by glucocorticoids

Comparison of systemic and local lung responses was analysed using blood and BAL samples from patients with severe/critical Covid-19 and showed that among (A)

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

cytokines (plasma n=9; BAL n=9), (B) AA (plasma n=29; BAL n=19), (C) 5-HETE (plasma n=29; BAL n=19), and (D) 11-HETE (plasma n=29; BAL n=19), levels of only AA were higher in blood. (E) The ACh concentration (pmol.mL⁻¹) in heparinized plasma from healthy-participants (n=6) compared to plasma from SARS-CoV-2-infected patients not treated with glucocorticoids (non-GC) classified as having asymptomatic-to-mild (n=5), moderate (n=9), severe (n=7), and critical (n=7) disease showed an increase based on disease severity. (F) ACh in the plasma of patients with Covid-19 at severe/critical stages of the disease and treated (GC, n=18) or not (non-GC, n=14) with glucocorticoids shows decreased release in response to the treatment. (G) Comparison of ACh in BAL from SARS-CoV-2-infected severe/critical patients treated (CG, n=17) or not (non-GC, n=3) with glucocorticoids confirmed inhibition of the neurotransmitter by the treatment. (H) Comparison of neutrophil numbers from blood (n=14) and BAL (n=14) of patients with severe/critical disease demonstrated increased neutrophil infiltration in the lungs. Data are expressed as the mean \pm SEM. Differences were considered significant at P<0.05 according to (A) and (E) Kruskal-Wallis tests followed by Dunn's posttest. (B, C, D, F and G) Student's t-tests, Mann–Whitney, (H) Wilcoxon matched-pairs signed rank test. Concentrations of ACh in the blood of patients with severe and critical disease and not treated with glucocorticoids were the same, as shown in panels (E) and (F). Blood and BAL were collected during hospitalization, on average 6 to 17 days after admission, and glucocorticoids (methylprednisolone; range 40 to 500 mg/kg/day, or dexamethasone; range 1.5 to 6.0 mg/kg/day) were administered intravenously. Interaction networks between various pairs of mediators quantified in (I) blood (n=151) or (J) BAL (n=32) from our Covid-19 cohort, as constructed using the open access software Cytoscape v3.3 (Cytoscape Consortium, San Diego, CA) and Spearman tests and showing significant correlations depicted by different lines (r and P values described in section 7.1). (K-P)

Venn diagram constructed according to the online tool Draw Venn Diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/) illustrates high-producing patients in severe and critical stages of disease, with (GC) or without (non-GC) treatment. (K-N) Plasma from patients producing high levels of AA, 5-HETE, 11-HETE, ACh and sCD14 in GC (n=49) or non-GC (n=17) groups. (O, P) BAL from patients producing high levels of AA, 5-HETE, 11-HETE, and ACh in GC (n=23) or non-GC (n=4) groups. For analysis, the global median between controls and patients was considered as the cut-off point. (Q) Summary data of the values used for construction of the Venn diagrams. The table shows the absolute number of patients present at each stage of the disease and whether glucocorticoids were used for each molecule analysed. The percentage of individuals present in each experimental condition is highlighted in brackets.

Figure 5. Re-analysis of transcriptome data reinforced the correlation between acetylcholine and arachidonic acid to Covid-19 severity and mortality.

(A) Gene coexpression profile from CVL, CVH, and NCV samples in principal module M1 (1047 genes, red lines) and mean gene expression (black line) (n=51). Genes identified as being associated with AA and ACh were only found in module M1; ten are related to cholinergic receptors and the ACh release cycle and eight to AA metabolism along with several biomarkers related to Covid-19 severity (Supplementary Appendix II; Table S4). (B) Heatmap of normalized gene expression related to the ACh and AA pathways and Covid-19 biomarkers (n=51). Almost all coexpressed genes of the ACh and AA pathways were upregulated in the CVL versus CVH group, including twelve cholinergic receptors, six ACh release cycle genes, eighteen AA production and metabolism pathway genes, and nine eicosanoid receptors (Figure S6A; Supplementary

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329


1330


1331


1332


Appendix III). Approximately 36% of these genes were also upregulated in the CVL versus NCV group but not in the CV versus NCV group (n=51); among them, elongation of very long-chain fatty acid protein 2 (ELOVL2) is involved in linoleic acid metabolism (Figure S6A; Supplementary Appendix III). Cases 3, 9, and 11 were glucocorticoidtreated patients. (C) First-order gene interaction network of the M1 module containing differentially expressed genes related to ACh (brown), AA (green), Covid-19 biomarkers (red), betweenness hubs (blue), and albumin genes (magenta – Covid-19 biomarker and hub). Ten DEGs related to ACh and ten DEGs of AA populated the biological network and are connected to thirteen genes involved in the pathophysiology of Covid-19 and CD36. ACh- and AA-related genes showed relatively low values of centrality metrics and may be under the action of some hub genes, such as oestrogen receptor II (ESR2), insulinlike growth factor II mRNA binding protein (IGF2BP1), albumin (ALB), and others (Supplementary Appendix IV). (D) Plasma and BAL levels of ACh (n=52). ACh levels in BAL fluid exhibited a tendency towards increase compared to plasma samples from deceased or discharged patients. (E) AA (n= 48) and AA concentrations were higher in plasma than in BAL in both patient groups. (F) 5-HETE (n=48) and (G) 11-HETE (n=47) in several/critical patients according to outcome (discharged or deceased). 5-HETE and 11-HETE levels were only significantly higher in the BAL of deceased patients. (H) Transcription levels of cholinergic muscarinic M3 receptor (CHRM3) and cholinergic receptor nicotinic alpha 7 (CHRNA7) (n=51) and (I) oxoeicosanoid receptor 1 (OXER1) (n=51). A unique gene expression profile in lung samples from Covid-19 patients who had died was characterized by high levels of pro-inflammatory cholinergic receptors (CHRM3, CHRNA3, and CHRNA5) 9,110, low levels of anti-inflammatory cholinergic receptor (CHRNA7) 113, and high expression of oxoeicosanoid receptor 1 (OXER1) 50 which mediates the pro-inflammatory effects of eicosanoids (Figures S6B, S6C). Other

eicosanoid and cholinergic receptors were also differentially expressed in CVL patients compared to the CVH or NCV group (Figures S6A, S6B, S6C). Finally, transcriptome analysis of fifteen Covid-19 and five non-Covid-19 samples indicated a correlation between ACh and AA genes and Covid-19 severity in some CVL patients. Significant differences in BAL/plasma levels of mediators were set at P< 0.05 according to the Kruskal-Wallis test followed by Dunn's posttest. *present in module M1. Abbreviations: Covid-19 low viral load (CVL) - Covid-19 high viral load (CVH) - non-Covid-19 (NCV).














Supplementary Tables

Table S1 – Classification of study participants

| Participant's classification | Symptoms, signs, and parameters |
|------------------------------|---|
| Group 1 Healthy-participants | Negative for SARS-Cov-2 nucleicacidNo clinical signs |
| Group 2 Asymp-to-mild | Positive for SARS-Cov-2 nucleic acid and/or serological test With or without the following symptoms: diarrhea, cough, fever, headache, loss of taste (ageusia)/smell (anosmia), myalgia, nausea, and vomiting |
| Group 3 Moderate | Oxygen saturation 94-99 % on room air Positive for SARS-Cov-2 nucleic acid and/or serological test Manifestation of mild disease symptoms including dyspnea Oxygen saturation ≥93% on room air PaO₂/FiO₂ 250-300mmHg Do not need invasive ventilation: nasal catheter (oxygen 2-4L/min) or oxygen reservoir (oxygen 4-10L/min) |
| Group 4 Severe | Positive for SARS-Cov-2 nucleic acid and/or serological test Admission to intensive-care units Severe respiratory distress Oxygen saturation <93% on room air PaO₂/FiO₂ <250mmHg Need no-invasive ventilation: oxygen reservoir or non-rebreathing face mask (oxygen 10-15L/min). |
| Group 5 Critical | Positive for SARS-Cov-2 nucleic acid and/or serological test Admission to intensive-care units Acute respiratory distress syndrome Need invasive ventilation PaO₂/FiO₂ <200mmHg With or without one or more additional parameters: need hemodialysis, sepsis, septic shock, and multiorgan dysfunction |

The participants were classified into five clinical groups (G1–G5): healthy participants (G1) and Covid-19 patients (G2 to G5), based on the severity of disease, clinical parameters, patient's management, and laboratory findings, following the recommendations from WHO $^{132-137}$. These classifications were used to define the scale of the clinical progression of patients. The inclusion criteria were as follows: (i) signed informed consent form; (ii) fit into one of the five clinical groups; (iii) healthy participants must be negative for SARS-CoV-2 nucleic acid; (iv) asymptomatic or symptomatic participants must be positive for SARS-CoV-2 nucleic acid and/or anti-SARS-CoV-2 antibody; (v) age ≥ 12 years. Participants from groups G1, G2, and G5 were 16

1356 years old or older, while the participants from groups G3 and G4 were 12 years old or older. 1357 Pregnancy was the only exclusion criterion for healthy participants (G1). Abbreviations: FiO₂, 1358 fraction of inspired oxygen; PaO₂, partial pressure of oxygen. 1359

 $Table \ S2-Data \ of \ demographic, \ clinical, \ and \ blood \ findings \ (n=229)$

| | Healthy- | All patients | • - | COVID-19 | care | | _ P value |
|---|--------------|--------------|--------------|------------|-------------|-------------|------------------|
| Baseline Variable | participants | N= 190 | Asym-to-mild | Moderate | Severe | Critical | _ P value (§) |
| | N= 39 | | N= 43 | N= 44 | N= 54 | N= 49 | (3) |
| Demographic characteristics | | | | | | | |
| Age median ± SD, (IQR) | 36±16.06 | 53±18.42 | 39± 10.74 | 47± 16.90 | 62± 15.88 | 66± 16.63 | <0.001 |
| | (23-80) | (16-96) | (20-57) | (16-92) | (30-96) | (20-86) | |
| Gender, No. (%) | | | | | | | |
| Male | 19 (49) | 107 (56) | 18 (42) | 25 (57) | 30 (56) | 34 (69) | - 0.400 |
| Female | 20 (51) | 83 (44) | 25 (58) | 19 (43) | 24 (44) | 15 (31) | |
| Comorbidities or coexisting disorders, No. (%) | | | | | | | |
| Hypertension | 5 (13) | 77 (41) | 5 (12) | 11 (25) | 40 (74) | 21 (43) | <0.001 |
| Dyslipidemia | 8 (21) | 28 (15) | 7 (16) | 8 (18) | 8 (15) | 5 (10) | 0.102 |
| Diabetes <i>mellitus</i> | 1 (3) | 51 (27) | 3 (7) | 11 (25) | 25 (46) | 12 (24) | 0.002 |
| Obesity | 5 (13) | 36 (19) | 8 (19) | 11 (25) | 8 (15) | 9 (18) | 0.450 |
| Neurological Disease | - | 20 (11) | | 3 (7) | 8 (15) | 9 (18) | - |
| Respiratory Disorders | 1 (3) | 34 (18) | 12 (28) | 10 (23) | 3 (6) | 9 (18) | <0.001 |
| Symptoms, No. (%) | | | | | | | |
| Dyspnea | - | 103 (54) | 3 (7) | 35 (80) | 36 (67) | 29 (59) | - |
| ever | - | 57 (30) | 1 (2) | 10 (23) | 26 (48) | 20 (41) | - |
| Myalgia | = | 40 (21) | - | 8 (18) | 19 (35) | 13 (27) | - |
| Diarrhea | = | 48 (25) | 13 (30) | 13 (30) | 13 (24) | 9 (18) | - |
| Cough | - | 127 (67) | 25 (58) | 34 (77) | 41 (76) | 27 (55) | - |
| Anosmia | - | 59 (31) | 27 (63) | 19 (43) | 7 (13) | 6 (12) | - |
| Dysgeusia | - | 57 (30) | 25 (58) | 19 (43) | 8 (15) | 5 (10) | - |
| Headache | - | 13 (7) | | 4 (9) | 5 (9) | 4 (8) | - |
| aboratory findings, median ± SD, (IQR) | | | | - (-) | - (-) | - (-) | |
| - 1 (4091-1) | 4.7±0.48 | 4.4±0.88 | 4.8±0.46 | 4.5±0.71 | 4.4±0.99 | 3.7±0.67 | 0.000 |
| Erythrocytes (10 ⁹ L ⁻¹) | (4.0-5,8) | (1.1-5.9) | (3.9-5.9) | (2.9-5.9) | (1.1-5.9) | (2-5.8) | 0.0034 |
| 1 1 2 4 11-15 | 15.0±1.55 | 13.1±2.68 | 14.5±1.28 | 13.9±2.26 | 12.9±2.64 | 10.7±2.65 | |
| Hemoglobin (g dL ⁻¹) | (11.3-17.5) | (6.5-18.2) | (12.0-18.2) | (8.4-18.2) | (6.8-17.6) | (6.5-18.2) | 0.001 |
| 1 (4091-1) | 7.5±1.71 | 8.8±5.24 | 7.3±2.28 | 7.7±2.82 | 8.6±5.23 | 13.2±6.00 | |
| Leukocytes (10 ⁹ L ⁻¹) | (4.1-11.2) | (1.6-33.0) | (3.2-13.6) | (2.6-14.9) | (1.6-33.0) | (5.2-29.0) | 0.042 |
| 1.1 (4.091-1) | 4.2±0.99 | 6.3±4.90 | 4.1±1.76 | 4.9±2.72 | 6.8±4.31 | 11.4±5.36 | .0.000 |
| Neutrophils (10 ⁹ L ⁻¹) | (2.4-6.0) | (1.6-26.1) | (1.6-9.9) | (1.8-13.4) | (0.24-25.1) | (3.7-26.1) | <0.001 |
| 1h t (1091-1) | 2.5±0.85 | 1.4±0.93 | 2.3±0.67 | 2.0±0.90 | 1.1±0.82 | 0.9±0.54 | .0.001 |
| Lymphocytes (10 ⁹ L ⁻¹) | (1.2-5.1) | (0.1-4.3) | (1.2-4.3) | (0.3-4.2) | (0.1-4.1) | (0.2-2.6) | <0.001 |
| DAIL | 1.8±0.56 | 5.1± 14.93 | 1.7±0.62 | 3±5.61 | 6.6±18.23 | 11.9±18.30 | |
| RNL | (1-3.1) | (0.6-115.4) | (0.7-3.6) | (0.6-29.7) | (1.3-115.4) | (3.4-92) | <0.001 |
| Manager (109 L-1) | 0.5±0.17 | 0.5±0.38 | 0.5±0.17 | 0.4±0.23 | 0.5±0.45 | 0.5±0.52 | |
| Monocytes (10 ⁹ L ⁻¹) | (0.3-0.9) | (0.0-2.6) | (0.3-0.9) | (0.1-1.2) | (0.0-2.0) | (0.0-2.6) | 0.207 |
| 21-4-1-4- (4091-1) | 216±37.34 | 236± 93.69 | 227±67.10 | 234± 88.93 | 251± 108.5 | 234±98.67 | |
| Platelets (10 ⁹ L ⁻¹) | (129-297) | (50-635) | (135-474) | (117-515) | (85-635) | (50-620) | 0.039 |
| Classic (see Hel) | 90±10.14 | 113.5±70.37 | 88±72.88 | 99.5±39.38 | 142±78.65 | 147.5±59.90 | |
| Glycemia (mg dL ⁻¹) | (76-113) | (28-479) | (65-479) | (65-262) | (28-409) | (76-301) | <0.001 |

| TTPa (seconds) | 26.0±2,49 | 26.7±5.65 | 26.2±3.28 | 26.6±4.80 | 27.8±3.66 | 26.7±9.38 | 0.167 | |
|---|-------------|------------|-------------|-------------|-------------|------------|--------|--|
| Tira (seconds) | (21.8-31.7) | (0.0-64.1) | (20.4-38.6) | (18.2-41.4) | (20.5-35.2) | (0.0-64.1) | 0.167 | |
| TP (seconds) | 13.6±1.68 | 13.1±2.1 | 13.3±1.29 | 13.2±1.17 | 12.6±2.65 | 13.3±2.81 | 0.041 | |
| TP (Seconds) | (12.6-21.7) | (0.0-18.1) | (12.1-17.5) | (11.0-15.2) | (0.0-15.7) | (0.0-18.1) | 0.041 | |
| INR | 1.12±0.17 | 1.1±0.16 | 1.1±0.13 | 1.1±0.10 | 1.1±0.11 | 1.2±0.25 | 0.106 | |
| IINK | (1.0-1.97) | (0.0-1.6) | (1.0-1.5) | (0.9-1.4) | (1.0-1.4) | (0.0-1.6) | 0.106 | |
| Hospital support, No. (%) | | | | | | | | |
| Infirmary | - | 73 (38) | - | 20 (45) | 50 (93) | 3 (6) | - | |
| Intensive care unit (ICU) | - | 53 (28) | = | 3 (7) | 4 (7) | 46 (94) | - | |
| Hospitalization data, No. | | | | | | | | |
| Hospitalization days, median (IQR) | - | 10 (1-34) | - | 2 (1-23) | 9 (1-22) | 14 (4-34) | | |
| Infection data, median ± SD, (IQR) | | | | | | | | |
| I. C. P I | | 5±2.74 | | 5±2.54 | 5±2.97 | 5±2.58 | | |
| Infection days | - | (1-16) | - | (1-10) | (2-16) | (1-10) | | |
| Respiratory support received (%) | | | | | | | | |
| Nasal-cannula oxygen | - | 58 (31) | - | 18 (41) | 38 (70) | 2 (4) | - | |
| Non-rebreathing mask / Non-invasive ventilation | - | 21 (11) | - | - | 15 (28) | 6 (12) | - | |
| Invasive mechanical ventilation | - | 41 (22) | = | - | 1 (2) | 40 (82) | - | |
| Oxygen saturation median ± SD (IQR) | 98.0±2,16 | 94.0±11,00 | 98.0±1.79 | 97.0±4.40 | 90.5±15.3 | 91.5±9.84 | <0.001 | |
| Oxygen saturation median ± 3D (IQN) | (90-99) | (86-100) | (93-99) | (80-100) | (86-99) | (66-99) | <0.001 | |
| Denouement, No (%) | | | | | | | | |
| Discharge | - | 61 (32.1) | = | 20 (45.5) | 32 (59.3) | 9 (18.4) | - | |
| Death | - | 65 (34.2) | - | 3 (6.8) | 22 (40.7) | 40 (81.6) | - | |
| Medications No. (%) | | | | | | | | |
| Dexamethasone | - | 100 (53) | = | 14 (32) | 45 (83) | 41 (84) | - | |
| Azithromycin | - | 98 (52) | 1 (2) | 18 (41) | 52 (96) | 28 (57) | - | |
| Ceftriaxone | = | 110 (58) | 13 (30) | 17 (39) | 50 (93) | 30 (61) | - | |
| Oseltamivir | = | 64 (34) | = | 4 (9) | 37 (69) | 23 (47) | - | |
| Cloroquine/Hydroxycloroquine | - | 33 (17) | - | 3 (7) | 13 (24) | 17 (35) | - | |
| Anticoagulant | 1 (3) | 4 (2) | 1 (2) | - | - | 3 (6) | - | |
| Ivermectin | - | 2 (1) | - | 1 (2) | 1(2) | - | - | |

Abbreviations: N, number of participants; SD, standard deviation; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes; N (%); TTPa, activated partial thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of the control group (healthy participants) with all patients. The values were compared using the χ^2 test and one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. p<0.05 was considered statistically significant.

1367 Table S3 - Demographic, clinical characteristics and blood findings data from severe/critical participants of which bronchoalveolar lavage (BAL) were collected 1368 1369 (n=45)

| Baseline Variable BAL | non-Covid-19 Patients N= 13 | Covid-19 N= 32 | p Value (§) |
|--|---|----------------------------|----------------|
| Demographic characteristics | | | |
| Age median \pm SD, (IQR) | 61±21.2 (20 - 82) | 66.5±17 (25-86) | 0,4237 |
| Gender, No. (%) | | | 3,1237 |
| Male | 4 (30,8) | 21 (65.6) | - |
| Female | 9 (69,2) | 11 (4.4) | - |
| Comorbidities or coexisting disorders, N | | 16 (51.61) | 0.2052 |
| Hypertension Dvslipidemia | 4 (30.77) | 16 (51.61) 2 (6.45) | 0,2052 |
| Diabetes mellitus | 2 (15.38) | 8 (25.81) | 0,4517 |
| Obesity | 1 (7.69) | 3 (9.68) | 0,8345 |
| Neurological | 2 (15.38) | 4 (12.90) | 0,8268 |
| Respiratory disorders | 7 (53.85) | 3 (9.68) | 0,0014 |
| Presenting symptoms, No. (%) | | | |
| Dyspnea | 4 (30.8) | 18 (58.1) | |
| Fever | - | 14 (45.2) | - |
| Myalgia Diarrehea | <u>-</u> | 10 (32.3) 7 (22.6) | = |
| Cough | <u>-</u> | 18 (58.1) | - |
| Hyperactive Delirium | - | - | - |
| Dysgeusia | - | 3 (9.7) | - |
| Anosmia | - | 4 (12.9) | - |
| Astemia | - | 3 (9.7) | - |
| Laboratory findings, $median \pm SD$, (IQR) | | | |
| Erythrocytes (10 ¹² L ⁻¹) | 2.7±0.94 (1.6-5.2) | 3.5±0.70 (2-5.3) | 0,0175 |
| Hemoglobin (g dL ⁻¹) | 8.7±2.93 (4.6-15.2) | 10.3±2.19 (6.5-16.2) | 0,0319 |
| Leukocytes (10 ⁹ L ⁻¹) | 11.5±15.44 (7.8-62.4) | 11.8±6.70 (4.6-29.0) | 0,7848 |
| Neutrophils (10 ⁹ L ⁻¹) | 8.6±11.18 (4.5 - 45.5) | 9.6±5.95 (3.3-26.1) | 0,9842 |
| Lymphocytes (10 ⁹ L ⁻¹) | 1.2±1.08 (0.3-4.4) | 0.9±0.54 (0.4-2.2) | 0,2127 |
| RNL | 7±21.15 (2.6-73) 11.0 | | 0,2925 |
| Monocytes (10 ⁹ L ⁻¹) | 0.6±0.51 (0.3-1.8) | 0.6±0.55 (0-2.6) | 0,5627 |
| Platelets (10 ⁹ L ⁻¹) | 254±165.8 (71-553) | 252±86.8 (50 - 414) | 0,4519 |
| Glycemia (mg dL ⁻¹) | · • · · · · · · · · · · · · · · · · · · | | 0,5848 |
| TP | 13.2±1.97 (11.5-17.1) | 13.1±3.34 (0-18.1) | 0,8464 |
| TTPa | 25.5±6.30 (22.6-46) | 25.2±10.96 (0-64.1) | 0,6380 |
| INR Respiratory support received (%) | 1.1±0.18 (0.1-1.5) | 1.2±0.30 (0-1.6) | 0,9632 |
| Oxygen Saturation median ± SD (IQR) | 94±6.41 (78-100) | 91±10.36 (66-99) | 0.0500 |
| Hospitalization data, No. | | | 0,0500 |
| Hospitalization days, median (IQR) | 22±11.41 (6-43) | 14±15.36 (5-34) | 0,0888 |
| Infeccions data, median ± SD, (IQR) | 4+2.27 | 6±2.46 | , |
| Infection days | 4±3.27 (2-10) | 6±2.46 (0-11) | 0,3166 |
| Denouement, No (%) | 0 (60.5) | 4/22.0 | |
| Discharge Dooth | 9 (69.2) | 4 (12.9) | - |
| Death Medications No. (%) | 4 (30.8) | 28 (87.5) | - |
| Dexamethasone | 2 (15.38) | 26 (83.87) | < 0,000 |
| Azithromycin | 1 (7.69) | 2 (6.45) | 0,8816 |
| Ceftriaxone | 10 (76.92) | 25 (78.13) | 0,9300 |
| Oseltamivir | 1 (7.69) | 16 (51.61) | 0,0063 |
| Cloroquine/Hydroxycloroquine | 1 (7.69) | 10 (32.26) | 0,0860 |
| | - | - | = |
| Anticoagulant Ivermectin | 1 (7:09) - - | 10 (32.20) - - | |

Abbreviations: N, number or values; SD, standard deviation; IQR, minimum and maximum values; RNL, ratio between neutrophils and lymphocytes; N (%); TTPa, activated partial thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of the Covid-19 negative patients group with Covid-19 positive patients. The values were compared using the χ^2 test and one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. p<0.05 was considered statistically significant.

1379

1380

1381

1382

1383

1384

Table S4 - List of genes related to acetylcholine and arachidonic acid pathways and Covid-19 biomarkers founded in co-expression module M1

| Gene (symbol) | Gene (name) | Pathway or Biomarker |
|------------------|---|-------------------------|
| CHRM2 | cholinergic receptor muscarinic 2 | |
| CHRM3 | cholinergic receptor muscarinic 3 | |
| CHRM5 | cholinergic receptor muscarinic 5 | |
| CHRNA2 | cholinergic receptor nicotinic alpha 2 subunit | |
| CHRNA3 | cholinergic receptor nicotinic alpha 3 subunit | |
| CHRNA4 | cholinergic receptor nicotinic alpha 4 subunit | Acetylcholine |
| CHRNA5 | cholinergic receptor nicotinic alpha 5 subunit | |
| CHRNB2 | cholinergic receptor nicotinic beta 2 subunit | |
| PPFIA4 | PTPRF interacting protein alpha 4 | |
| RIMS1 | regulating synaptic membrane exocytosis 1 | |
| ALOX15 | arachidonate 15-lipoxygenase | |
| CYP4F3 | cytochrome P450 family 4 subfamily F member 3 | |
| CYP4A11 | cytochrome P450 family 4 subfamily A member 11 | |
| CYP8B1 | cytochrome P450 family 4 subfamily B member 1 | |
| CYP4F8 | cytochrome P450 family 4 subfamily F member 8 | Arachidonic acid |
| CYP2C8 | cytochrome P450 family 2 subfamily C member 8 | |
| CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | |
| DPEP2 | dipeptidase 2 | |
| ALB | Albumin | |
| CRP | C-reactive protein | |
| CXCL8 (IL8) | C-X-C motif chemokine ligand 8 | Biomarker |
| FGA | fibrinogen alpha chain | (COVID-19) |
| FGB | fibrinogen beta chain | |
| IL1β | interleukin 1 beta | |
| IL1β | interleukin 1 beta | |

Co-expression analysis generated five different co-expression gene modules (M1 to M5) and only in M1 we identified genes that encoding proteins associated to cholinergic receptors (muscarinic and nicotinic), ACh release cycle, and AA metabolism. In addition, the M1 module also contains some biomarkers related to

1385 Covid-19 severity (albumin, C-reactive protein, IL-8, fibringen, and IL18) 1386 21,34,138,139

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

Table S5 - Treatment of severe and critical Covid-19 patients with glucocorticoids does not alter the levels of plasmatic cytokines and circulating neutrophils and lymphocytes

| | Severe non-GC N=3 | Severe GC N=39 | P value (#) | Critical non-GC N=4 | Critical GC N=17 | P value (§) |
|----------------|--------------------------|---------------------------|----------------|---------------------------|--------------------------------------|----------------|
| Parameters, me | dian ± SEM, (I | QR) | | | | |
| IL-8 | 31.7±12.6 (13.6-56.0) | 26.3±4.97 (2.8-186.4) | 0.454 | 26.86±6.5 (10.2-41.8) | 113.2±48.8 (13.1-661.9) | 0.144 |
| IL-6 | 42.7±20.1 (4.80-73.2) | 54.9±14.19 (3.3-414.1) | 0.782 | 46.4±13.2 (24.7-81.7) | 317.7 ±160.3 | 0.410 |
| IL-1 | 2.5±2.5 (0.0-7.6) | 0.1±0.05 (0.0-1.7) | 0.104 | 0.9±0.9 (0.0-3.6) | (11.3-2510) 0.5±0.3 | 0.874 |
| TNF | 0.0±0.0 (0.0-0.0) | 0.01±0.1 (0.0-0.3) | >0.999 | 0.8±0.8 (0.0-3.1) | (0.0-3.8) 0.04±0.04 | 0.191 |
| IL-10 | 1.0±0.5 (0.4-2.1) | 2.7±0.4 (0.3-9.1) | 0.165 | 2.3±1.1 (0.8-4.3) | (0.0-0.7) 7.5 ±2.6 | 0.229 |
| Neutrophils | 56.5±20.8 (15.0-77.5) | 80.5±1.7 (38.6-97.0) | 0.097 | 79.9±3.8 (73.1-89.0) | (0.1-45.1) 85.6±1.5 | 0.197 |
| Lymphocytes | 9.7±1.6 (8.0-13.0) | 12.0±0.9 (2.0-27.8) | 0.490 | 10.9±2.2 (5.0-14.7) | (70.1-93.0) 7.9±1.0 | 0.156 |
| RNL | 5.7±2.2 (1.9-9.4) | 10.2±1.6 (2.2-47.5) | 0.403 | 9.0±2. 7 (5.1-16.6) | (4.0-20.5) 13.3±1.5 (3.4-23.3) | 0.140 |

Abbreviations: N, number of participants; SEM, standard error of the mean; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes. §Comparison of the severe non-GC group with the severe GC group, and the critical non-GC group with the critical GC group. The values were compared using the χ^2 test, one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. p<0.05 was considered statistically significant.

As shown in the table, glucocorticoid therapy in severe Covid-19 patients did not show a statistically significant influence on the plasma levels of the cytokines evaluated in our study. The use of glucocorticoids and their impact on the production of inflammatory molecules is closely associated with several factors, such as the dose, duration, and time of initiation of therapy, since,

in the critical stages of Covid-19, no beneficial effects of glucocorticoids have been observed in the inflammation control and patient outcome ^{70,71}.

Table S6 - Impact of glucocorticoid therapy in the outcome of hospitalized Covid-

19 patients

| | Moderate | | Seve | re | Critical | | |
|---------|-----------------|---------|-----------|-----------|-----------|-----------|--|
| | N=23 | | N=54 | | N=49 | | |
| _ | Discharge Death | | Discharge | Death | Discharge | Death | |
| No, (%) | N=20 | N=3 | N=32 | N=22 | N=9 | N=40 | |
| non-GC | 7 (35) | 0 (0) | 4 (12.5) | 3 (13.6) | 4 (44.4) | 9 (22.5) | |
| GC | 13 (62) | 3 (100) | 28 (87.5) | 19 (86.4) | 5 (55.6) | 31 (77.5) | |

Abbreviations: N, number of participants (%).

Hospitalised Covid-19 patients from the moderate, severe, and critical groups were administered glucocorticoid (GC) therapy or not (non-GC) (methylprednisolone; range 40 to 500 mg/kg/day, or dexamethasone; range 1.5 to 6.0 mg/kg/day, by intravenous route). Most hospitalised patients were treated with glucocorticoids (moderate [69.6%], severe [87.0%], and critical [73.5%]). All moderate non-GC-patients were discharged, while GC patients had a mortality rate of 18.8%. In addition, the mortality rates for severe-GC (40.4%) and critical-GC (86.1%) patients were higher than those for moderate-CG patients. The discharge rates of non-GC patients vary according to the clinical categorization (100.0%, 57.1%, and 30.8% for moderate, severe, and critical, respectively). Hospitalised Covid-19 patients from our cohort showed fewer benefits of glucocorticoid therapy than those reported in the RECOVERY trial ⁶⁸, but similar benefits to those described in the CoDEX trial conducted in Brazil ⁶⁹. This reduction of glucocorticoid benefits could be associated with several factors, including a low mean PaO₂:FiO₂ ratio and an overload of the health systems of countries with limited resources, such as Brazil ⁶⁹, as well as glucocorticoid dose, initiation, and duration of therapy ^{70,71}.

Table S7 – Analysis of the potential interference of Covid-19-confounding variables on the correlation between high plasma levels of cholinergic and lipid mediators and Covid-19 severity.

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

| Confounding variables | Healthy participants | Asym-to-mild | Moderate | Severe | Critical | P <i>value</i> (§) | | | |
|---|-------------------------|--------------|------------|------------|------------|-----------------------|--|--|--|
| Lipid mediators (AA, 5-HETE, and 11-HETE) | | | | | | | | | |
| No | 17 | 10 | 11 | 16 | 11 | | | | |
| Age, mean (I QR) | 33 (27-44) | 33 (26-43) | 39 (30-48) | 57 (48-78) | 71 (57-78) | <0.001 | | | |
| Gender, No (%) Male | | | | | | 0.795 | | | |
| Female | 7 (41.2) | 5 (50.0) | 6 (54.5) | 7 (43.8) | 7 (63.6) | | | | |
| Diabetes, No (%) | 10 (58.8) | 5 (50.0) | 5 (45.5) | 9 (56.2) | 4 (36.4) | | | | |
| Hypertension, No (%) | 1 (5.9) | 1 (10.0) | 3 (27.3) | 6 (37.5) | 2 (18.2) | 0.183 | | | |
| Obesity, No (%) | 2 (11.8) | 0 (0.0) | 0 (0.0) | 12 (75.0) | 6 (54.5) | <0.001 | | | |
| | 4 (23.5) | 2 (20.0) | 3 (27.3) | 2 (12.5) | 1 (9.1) | 0.7788 | | | |
| | | ACh | | | • | | | | |
| No | 6 | 5 | 4 | 6 | 8 | | | | |
| Age, mean (IQR) | 30 (24-56) | 42 (38-46) | 48 (39-57) | 75 (63-79) | 65 (52-74) | 0.026 | | | |
| Gender, No (%) Male | | | | | | 0.290 | | | |
| Female | 4 (66.7) | 3 (60.0) | 2 (50.0) | 1 (16.7) | 6 (75.0) | | | | |
| Diabetes, No. (%) | 2 (33.3) | 2 (40.0) | 2 (50.0) | 5 (83.3) | 2 (25.0) | | | | |
| Hypertension, No. (%) | 0 (0.0) | 1 (20.0) | 1 (25.0) | 3 (50.0) | 1 (12.5) | 0.282 | | | |
| Obesity, No. (%) | 2 (33.3) | 2 (40.0) | 1 (25.0) | 5 (83.3) | 3 (37.5) | 0.360 | | | |
| | 1 (16.7) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 2 (25.0) | 0.767 | | | |

We analysed some confounding variables associated with Covid-19, such as comorbidities (Diabetes mellitus, hypertension, and obesity) and risk factors (advance age and gender) 51,140, using data from participants whose plasma levels of lipid mediators (AA, 5-HETE, and 11-HETE) and ACh were measured. Lipid mediators data came from Covid-19 patients and heathy participants presented in Figure 1 (Panels: F, G, and H), while ACh data came from glucocorticoid-non-treated Covid-19 patients presented in Figure 4E. Age and hypertension or only age are potential confounding variables on the correlation between high plasma levels of lipid mediators or ACh and Covid-19 severity, because (i) age had significant Spearman's correlation with AA (r=0.36; P=0.0042), 5-HETE (r=0.36; P=0.0042), and ACh (r=0.37; P=0.0485); and (ii) hypertensive patients had significantly increased plasma levels of AA (p=0.0062 - Mann-Whitney test). Kruskal-Wallis or Fisher's tests were used to compare the differences between all clinical categories. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered statistically significant.

Table S8 - Analysis of the potential interference of Covid-19-confounding variables on the correlation between high ACh levels in severe/critical patients, treated or not with glucocorticoids, and Covid-19 severity.

| Severe (Plasm) | | | | Cri | Critical (Plasm) | | | Critical (BAL) | | |
|---------------------|--------------|------------|----------------|------------|------------------|----------------|------------|----------------|----------------|--|
| Confounding variabl | es non-GC | GC | P value (§) | non-GC | GC | P value (§) | non-GC | GC | P value (§) | |
| No | 6 | 10 | | 8 | 8 | | 3 | 17 | | |
| Age, median | 75 (63-79) | 68 (55-76) | 0.415 | 65 (52-74) | 76 (60-79) | 0.316 | 74 (72-80) | 62 (53-76) | 0.243 | |
| (IQR) Gender, No | | | 0.118 | | | 1.000 | | | 0.920 | |
| (%) Male | 1 (16.7) | 7 (70.0) | | 6 (75.0) | 6 (75.0) | | 2 (66.7) | 11 (64.7) | | |
| Female Diabetes, | 5 (83.3) | 3 (30.0) | | 2 (25.0) | 2 (25.0) | | 1 (33.3) | 6 (35.3) | | |
| No (%) | 4 (40.0) | 6 (60.0) | 1.000 | 1 (12.5) | 3 (37.5) | 0.569 | 1 (33.3) | 3 (17.6) | 0.450 | |
| Hypertension, No | 2 (20.0) | 8 (80.0) | 1.000 | 3 (37.5) | 5 (62.5) | 0.619 | 3 (100.0) | 6 (35.3) | 0.073 | |
| (%) Obesity, No (%) | 0 (0.0) | 1 (10.0) | 1.000 | 2 (25.0) | 2 (25.0) | 1.000 | 0 (0.0) | 3 (17.6) | 1.000 | |

Here we used the same confounding variables associated with Covid-19 described on Table S7. This analysis was based on plasma and BAL cholinergic mediator (ACh) data from severe/critical Covid-19 patients, treated (GC) or not (non-GC) with glucocorticoids, and reported in Figure 4 (Panels: F and G). None of the confounding variables tested had significant potential to interfere with the glucocorticoid-therapy ability to reduce the high plasma and BAL ACh levels in severe/critical patients. §Mann-Whitney or Fisher's tests were used to compare the differences between severe and critical clinical categories. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered statistically significant.

Table S9 - Impact of Covid-19 confounding variables on the comparative analysis between high levels of lipid mediators in plasma and BAL samples from severe and critical patients.

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461


| Confounding variables | Severe/Critical (Plasm) | Severe/Critical (BAL) | P value (§) |
|-----------------------|----------------------------|--------------------------|----------------|
| No | 25 | 18 | |
| Age, median (IQR) | 60 (53-77) | 64 (52-83) | 0.6395 |
| Gender, No. (%) Male | | | 0.1394 |
| Female | 14 (56.0) | 14 (77.8) | |
| Diabetes, No. (%) | 11 (44.0) | 4 (22.2) | |
| Hypertension, No. (%) | 7 (28.0) | 5 (27.8) | 0.9872 |
| Obesity, No. (%) | 16 (64.0) | 9 (50.0) | 0.3586 |
| | 3 (12.0) | 4 (22.2) | 0.4274 |

We used the same confounding variables associated with Covid-19 reported on Table S7. This analysis was based on plasma and BAL levels of lipid mediators (AA, 5-HETE, and 11-HETE) from severe/critical Covid-19 patients reported in Figure 4 (Panels: B, C, and D). None of the confounding variables tested had significant potential to interfere with the comparison between altered plasm and BAL levels of lipid mediators in severe/critical patients. §Mann-Whitney, chisquare, or Fisher's tests were used to compare the differences between severe and critical patients. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered statistically significant.

Supplementary Figures

Figure S1 – Metabolic signatures of plasma and BAL samples from patients

infected or not with SARS-CoV-2.



Hierarchical clustering based on different characteristics of abundant metabolites (ANOVA-FDR <0.1) between controls and patients positive for SARS-CoV-2 at different stages of the disease in plasma (A) and non-Covid-19 versus Covid-19 BAL patients (B). In (A), the clinical classification of Covid-19 was: healthy participants (n=20), asymptomatic-to-mild (n=10), moderate (n=12), severe (n=16), and critical (n=13) groups. In (B), the same analysis was performed with data from BAL samples of non-Covid-19 (n=12) and Covid-19 (n=26) patients. The detection levels of metabolites were defined using Z-score normalisation.

The analysis of hierarchical clustering (A) shows highly different metabolomic profiles in the plasma for each group of individuals according to disease severity. BAL analysis (B) of samples from Covid-19 patients demonstrated an increase in the abundance of metabolites compared to non-Covid-19 individuals. The results indicated that SARS-CoV-2 infection induces

1478


1479

1480

1481

changes in the metabolic profile of humans. Our data are in agreement with previous results showing virus-induced metabolic reprogramming in the host. The increased abundance of metabolites and their pathways, such as free fatty acids and amino acids, was correlated to the increase in viral proliferation, since these biomolecules can act as building blocks and fuel for this process 141-143.


Figure S2 - Gating strategy used for flow cytometry analysis of monocyte subsets and CD14/CD36 expression



In (A), dot plots show a representative gating strategy for the analysis of FSC-H/FSC-A, SSC-A/FVS-620 (viable cells), and SSC-A/FSC-A, followed by CD14⁺HLA-DR⁺ monocytes and the classical (CD14^{high}CD16⁻), intermediate (CD14⁺CD16⁺) or non-classical CD14^{low}CD16⁺ subsets, with subsequent CD36 mean fluorescence intensity (MFI) in whole blood (upper panel) and bronchoalveolar lavage fluid (BAL, bottom panel). In (B), a violin plot shows the frequency of non-classical monocytes from BAL of non-Covid-19 and Covid-19 patients. In (C), CD36 MFI in classical, intermediate, and non-classical monocytes from BAL of non-Covid-19 and Covid-19 samples. Differences between groups were calculated using the Mann-Whitney test.

The membrane markers and gating strategies used to define the different monocyte subpopulations in the blood and BAL samples were adapted from a previous publication (ref). In BAL, there was a tendency to reduce non-classical monocytes in Covid-19 patients compared to non-Covid-19 patients (Figure 2SB), as well as a decrease in CD36 expression in classical and intermediate monocytes (Figure 2SC), although the difference was not statistically significant. Although not significantly, this reduction may have a biological importance. These data are similar to the profile observed in the blood monocytes of Covid-19 patients (Figure 3J).

Figure S3 - Determination of monocyte subsets in the blood and BAL samples from non-Covid-19 and Covid-19 patients



Peripheral blood from healthy participants (n=12), and asymptomatic-to-mild (n=15), moderate (n=15), severe (n=35), or critical (n=20) patients, and BAL from Covid-19 (n=10) and non-Covid-19 (n=11) participants were collected and used for the characterisation of monocyte subpopulations by flow cytometry and t-distributed stochastic neighbour embedding (t-SNE) analysis. (A) Frequency of CD14⁺HLA-DR⁺ cells. (B) t-SNE evaluation of classical (CD14^{high}CD16⁻), intermediate (CD14⁺CD16⁺),

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530


1531

1532

1533

and non-classical CD14^{low}CD16⁺ blood monocytes in Covid-19 patients, categorised according to disease severity. (C) Colour mapping t-SNE and violin plot showing the mean fluorescence intensity (MFI) of HLA-DR expression in the circulating monocytes of Covid-19 subjects. In (D) and (E), samples of BAL from non-Covid-19 and Covid-19 patients were evaluated to determine the frequency of CD14⁺HLA-DR⁺ cells and classical, intermediate, or non-classical monocyte subsets, respectively. Differences among groups were calculated using the Kruskal-Wallis test with Dunn's multiple comparison post-test, and the corresponding values are indicated in the figures. In comparison to healthy participants (Figure S3A, S3B, and 3SC), a significant reduction was observed in the intermediate monocyte population, as well as in the expression of HLA-DR molecules in the blood of Covid-19 patients, depending on disease severity. The diminishment of HLA-DR in monocytes correlated with TNF values obtained in the blood of patients positive for SARS-CoV-2 (Figure 2P; principal article), since monocytes with a pro-inflammatory profile are the main producers of this cytokine ¹⁴⁴. Similarly, reduced intermediate monocytes were found in the BAL of patients positive for Covid-19 (Figure S3E). Interestingly, these patients also had a significant increase in the production of IL-8, IL-10, and IL-6 cytokines in the blood and BAL, as shown before (Figure 2M, 2N, and 2Q and Figure 4A; principal article). The high production of cytokines, especially IL-6, in patients with Covid-19, has been correlated with a decrease in the expression of HLA-DR in monocytes, while the therapeutic inhibition of IL-6 reestablished the expression of this molecule in those individuals ¹⁴⁵

Figure S4 - Biomarker networks in non-Covid-19 and healthy participants




A network of interactions between lipid mediators, ACh, sCD14, and cytokines in (A) healthy participants (n=39) and (B) BAL non-Covid-19 participants (n=13). Network layouts of personalised biomarkers were set up to identify the relevant association in healthy and non-Covid-19 participants. Each connecting line denotes a significant correlation between a pair of markers. Continuous lines represent positive correlations, while dashed lines represent negative correlations (p<0.05). The degree of significance is represented by the thickness of the line. Correlations were determined using Spearman's test; the values of r and p were used to classify the connections as weak (r<0.35, p<0.05), moderate (r=0.36–0.67, p<0.01), or strong (r<2.0.68, p<0.001). The absence of a line indicates the non-existence of the relationship. To evaluate the relationship between levels of lipid mediators, ACh, sCD14, and cytokines in non-Covid-19, a series of correlation analyses were performed.

When comparing the interactions analysed between the molecules of the healthy and non-Covid-19 groups, we observed that (A) In the blood of healthy individuals, the interactions were found to occur mainly between cytokines (IL-1β, TNF, IL-8, IL-6, and IL-10) and the lipid mediator 5-HETE. (B) In thee BAL samples from hospitalised non-Covid-19 patients, lipid mediators were found to mediate these interactions and influence the clinical outcomes of this group of patients.

Figure S5 – Treatment of severe and critical SARS-CoV-2-infected patients with

glucocorticoids inhibits ACh release



The production of lipid mediators and the shedding of sCD14 in patients with Covid-19 at the severe and critical stages was not modified by treatment with glucocorticoids (GC). However, a marked reduction was observed in ACh release. Intersection analysis depicted in Venn diagrams revealed the number of patients producing AA, 5-HETE, 11-HETE, ACh, or sCD14, above the control (healthy participants) values, in the absence (A) or presence (B) of GC therapy. The table shows the number (n) of plasma or BAL samples from Covid-19 patients at the severe and critical stages of disease, for each mediator. The percentages shown in parentheses represent the frequency of patients producing the respective mediator for the corresponding sample number.

The Venn diagrams show the intersections of AA, 5-HETE, 11-HETE, ACh, and sCD14s in Covid-19 patients at the severe and critical stages of the disease, in both blood and BAL. No significant changes were observed in the quantification of lipid mediators or sCD14, comparing patients treated with or without glucocorticoids (Figure S5A and FigureS5B). Interestingly, critically ill patients treated with glucocorticoids showed a 20% and 65% reduction in the ACh

concentration in both blood and BAL samples, respectively, compared to patients who were not administered drugs (Figure S5B). While a decrease in free-AA and its metabolites (5-HETE and 11-HETE) has not been reported in the literature, some studies have demonstrated the beneficial effects of the use of glucocorticoids in other respiratory syndromes, having been found to reduce the production of AA-derived mediators 72,146. In agreement with our results, there is no evidence to support corticoid treatment for Covid-19 147. Data related to the effect of glucocorticoids on ACh release in viral infections are scarce. However, according to our previous findings on scorpion envenomation³, glucocorticoid treatment should be initiated early after infection to block the release of lipid mediators, which could lead to the inhibition of premature ACh release. On the contrary, the late administration of GC could place patients at a point of no return, with early ACh release impacting vital organs, damaged by the negative impacts of this neurotransmitter before GC administration. Moreover, it should be considered that, in Covid-19, other unknown mechanisms may control ACh release, in addition to the COX-2 dependent metabolites.

Figure S6 - Differential expression and profile of genes involved in AA and ACh pathways from SARS-CoV-2 deceased patients

1584

1585

1589


1590

1591

1592

1593

1594



Abbreviations: CVL, Covid-19 low viral load; CVH, Covid-19 high viral load; NCV, non-Covid-19 viral load ^{9,50,110,113}.

As shown in (A), DEGs were upregulated in CVL versus CVH patients and CVL versus NCV patients. The transcript expression of cholinergic receptors (muscarinic and nicotinic) (B) and eicosanoid receptors (C) was normalised in the NCV, CVH, and CVL groups. CVL patients displayed increased pulmonary levels of expression of genes

1596

1597

1598

1599

1600

associated with the ACh and AA pathways, encoding for cholinergic receptors, the ACh release cycle, AA metabolism, and eicosanoid receptors, compared to CVH or NCV patients. The expression profile of some genes may favour inflammatory events, such as upregulated cholinergic and eicosanoid receptors (CHRM3, CHRNA3, CHRNA5, and OXER1) and low levels of the anti-inflammatory cholinergic receptor (CHRNA7) 9,50,110,113